



The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Mohammed Eslam¹ · Shiv K. Sarin² · Vincent Wai-Sun Wong³ · Jian-Gao Fan⁴ · Takumi Kawaguchi⁵ · Sang Hoon Ahn⁶ · Ming-Hua Zheng^{7,8} · Gamal Shiha^{9,10} · Yusuf Yilmaz^{11,12} · Rino Gani¹³ · Shahinul Alam¹⁴ · Yock Young Dan¹⁵ · Jia-Horng Kao^{16,17,18,19} · Saeed Hamid²⁰ · Ian Homer Cua²¹ · Wah-Kheong Chan²² · Diana Payawal²³ · Soek-Siam Tan²⁴ · Tawesak Tanwandee²⁵ · Leon A. Adams²⁶ · Manoj Kumar² · Masao Omata^{27,28} · Jacob George¹

Received: 8 July 2020 / Accepted: 6 September 2020
© Asian Pacific Association for the Study of the Liver 2020

Abstract

Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s12072-020-10094-2>) contains supplementary material, which is available to authorized users.

✉ Mohammed Eslam

mohammed.eslam@sydney.edu.au

✉ Shiv K. Sarin

shivsar@ gmail.com

✉ Jacob George

jacob.george@sydney.edu.au

¹ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, NSW 2145, Australia

² Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India

³ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China

⁴ Center for Fatty Liver, Department of Gastroenterology, Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China

⁵ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan

⁶ Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

⁷ Department of Hepatology, MAFLD Research Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

⁸ Institute of Hepatology, Wenzhou Medical University, Wenzhou, China

⁹ Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt

¹⁰ Egyptian Liver Research Institute and Hospital (ELRIAH), Sherbin, El Mansoura, Egypt

¹¹ Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey

¹² Institute of Gastroenterology, Marmara University, Istanbul, Turkey

¹³ Department of Internal Medicine, Hepatobiliary Division, Dr. Cipto Mangunkusumo National General Hospital, Universitas Indonesia, Pangeran Diponegoro Road No. 71st, Central Jakarta 10430, Indonesia

¹⁴ Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Shahbag, Dhaka, Bangladesh

¹⁵ Department of Medicine, Yong Loo Lin School of Medicine, National University Singapore, Singapore, Singapore

¹⁶ Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, National Taiwan University, 1 Chang-Te Street, Taipei 10002, Taiwan

¹⁷ Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

¹⁸ Hepatitis Research Center, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan

¹⁹ Department of Medical Research, National Taiwan University, National Taiwan University Hospital, Taipei, Taiwan

epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector.

Introduction

The Asia-Pacific region with at least 55 countries is home to more than half of the world's population and accounted for 62.6% of liver-related deaths in 2015 [1]. Though there are substantial disparities in rates of development within the political, economic, and educational spheres, the entire region is moving towards urbanisation, shifting from an agrarian diet towards increased consumption of energy dense, nutrient poor foods, a sedentary lifestyle, and reduced physical activity. Similar to other affluent nations, this change has led to an increase in prevalence of disorders related to poor metabolic health. As would be expected from this, metabolic associated fatty liver disease (MAFLD) (formerly known as non-alcoholic fatty liver disease (NAFLD)) has risen in prevalence to alarming levels, placing an enormous burden on individuals and health-care systems [2]. This document presents the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The authors performed a systematic review of the literature retrieved after an extensive PubMed

search up to April 2020 on specified domains of interest and translated this scientific evidence into practice guidelines with recommendations to improve the assessment and management of patients with MAFLD.

These guidelines cover various aspects in the management of MAFLD including epidemiology, diagnosis, screening, assessment, and treatment. The statements in this document follow the Grading of Recommendation Assessment, Development, and Evaluation approach (Table 1).

The document was intended for practical use and for setting the stage for advancing knowledge and research of MAFLD in adults, with specific reference to special groups whenever necessary. The final purpose was to improve patient care and awareness of MAFLD and to assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector. A summary of all the recommendations is provided in Supplementary Table 1. Since it is expected that new evidence will emerge on the implications of adopting the MAFLD criteria, updates to these guidelines might be required in future.

Epidemiology

Emerging evidence based on several large population-based studies has demonstrated an exponential increase in MAFLD burden in the Asia-Pacific region over the past three decades [1]. A recent systematic review and meta-analysis of MAFLD prevalence from an Asian context and comprising > 13,044,518 individuals suggested that the prevalence of MAFLD in this region is 29.62% (95% CI 28.13–31.15) [4]. Within the Asia-Pacific region, MAFLD prevalence varies widely as would be predicted from tremendous variations in genetic background, nutrition, physical activity, lifestyle, and sedentary behavior. As expected, there is a bias in reported studies towards those that emanate from more affluent countries with more developed healthcare systems in the region [1].

Though there are no nationwide epidemiological surveys even within a single country such as China, there are substantial differences according to regions and over time in the prevalence of MAFLD. For instance, MAFLD prevalence in the populations from Shanghai (East China) was estimated to have increased from 15% before 2005 to 38.17% in 2012 [5, 6]. The prevalence in Xinxiang, Henan Province (Central China) was 29.85% in 2017 [7]. Similarly, in other regions of China, Chengdu (Southwest China) and Guangdong (South China), MAFLD prevalence rates were 12.5% and 17%, respectively [8, 9]. In Taiwan, the prevalence of MAFLD was estimated to be 11.4% in the general population [10] but was even higher in sub-populations such as the elderly (50.1%) [11] and among Taxi drivers, who typically have

²⁰ Department of Medicine, Aga Khan University, Karachi, Pakistan

²¹ Institute of Digestive and Liver Diseases, St. Luke's Medical Center, Global City, Philippines

²² Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

²³ Department of Medicine, Cardinal Santos Medical Center, Mandaluyong, Philippines

²⁴ Department of Hepatology, Selayang Hospital, Batu Caves, Malaysia

²⁵ Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

²⁶ Medical School, Faculty of Medicine and Health Sciences, The University of Western Australia, Nedlands, WA, Australia

²⁷ Department of Gastroenterology, Yamanashi Central Hospital, Yamanashi, Japan

²⁸ University of Tokyo, Tokyo, Japan

Table 1 Evidence grade used for the APASL Clinical Practice Guidelines on MAFLD (adapted from the GRADE system [3])

Grading of evidence	Notes	Symbol
High quality	Further research is very unlikely to change our confidence in the estimate effect	A
Moderate quality	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate effect	B
Low or very low quality	Further research is very likely to have an important impact on our confidence in the estimate of effect and may change the estimate effect. Any estimate of effect is uncertain	C
Grading of recommendations	Notes	Symbol
Strong recommendation warranted	Factors influencing the strength of the recommendation included the quality of the evidence, presumed patient-important outcomes, and cost	1
Weaker recommendation	Variability in preferences and values, or more uncertainty: more likely a weak recommendation is warranted	2
	Recommendation is made with less certainty; higher cost or resource consumption	

inactive lifestyles (66.4%) [12]. In Hong Kong, a community proton-magnetic resonance spectroscopy (MRS)-based study suggested the prevalence of 28.8%; 19.3% in non-obese subjects, and 60.5% among the obese [13].

In the Far East, the community prevalence of MAFLD was found to be 23–26% while 27.3% of subjects undergoing routine health screening demonstrated fatty liver by abdominal ultrasonography in Japan and Korea, respectively [14, 15]. Notably, in Japan, the prevalence of MAFLD has increased from 12.6% before 1990 to 30.3% in 1998 [16].

In rural India, a region characterized by traditional lifestyles and diets, the prevalence of MAFLD is remarkably low (~9%), while it mimics other Asian country prevalence rates in urban populations (16–32%) [17–19]. A nationwide community ultrasound-based study from Bangladesh of 2782 participants observed that the overall prevalence of MAFLD was 33.86% with no difference between urban and rural populations suggesting that Bangladesh has one of the highest rates of MAFLD in South Asia [20]. A similar dramatic variation in MAFLD prevalence (5–30%) was observed in smaller reports from Singapore, Malaysia, Sri Lanka, and Indonesia [21–24]. Differences in the prevalence of MAFLD was also observed among Asians of different ethnicities; for example, in multi-ethnic studies from Malaysia, the prevalence of MAFLD is consistently higher among ethnic Malays and Indians compared with ethnic Chinese; this ethnic predilection is observed as early as young adulthood [23, 25, 26].

Thus, while MAFLD rates are varied, there is a common trend to increasing prevalence with time. This has meant that the prevalence of MAFLD between the East and West is more similar than different and is beginning to approximate each other and in some cases, to exceed that in the West (e.g., in Pacific Island nations). Given the high prevalence of viral hepatitis in the region and as previous diagnostic criteria are based on the exclusion of other liver diseases, it may result in under-reporting of the true burden of MAFLD.

This further highlights the urgent need for “positive criteria” for disease diagnosis.


Few studies have examined the incidence of MAFLD in Asia. A recent meta-analysis (18 studies) suggested that the annual MAFLD incidence rate in Asian countries was 50.9 cases per 1000 person-years (95% CI 44.8–57.4) [4]. In a population study in Hong Kong using paired MRS, 13.5% (95% CI 10.6–16.3%) of the studied cohort developed MAFLD over an interval of 3–5 years, with an annual incidence of MAFLD estimated at 3.4% [27].

Definition and diagnosis of MAFLD

Interest in fatty liver diseases not due to alcohol has risen dramatically, in large part driven by its increased global prevalence. However, this disease is highly heterogeneous and thus placing all patients with a diverse and differential array of disease drivers under the acronym NAFLD can negatively impact clinical decision-making. Further, NAFLD is a diagnosis of exclusion rather than one of inclusion.

To address these issues, APASL endorses the proposal of a consensus panel of leading experts who proposed that a more appropriate nomenclature for the disease would be “metabolic associated fatty liver disease” or MAFLD [28]. The major benefit of this new nomenclature is a shift towards a diagnosis of inclusion based on the presence of metabolic dysfunction, the key driver of the disease. The new algorithm is developed from “positive criteria” regardless of alcohol consumption or other concomitant liver diseases (Fig. 1) [29]. In addition, this new nomenclature helps to identify a homogenous group of patients and will guide efforts for stratification of patients with MAFLD. As summarized in the paper, the diagnosis of MAFLD is based on the detection of liver steatosis (liver histology, non-invasive biomarkers or imaging) together with the presence of at least one of three criteria that includes overweight or obesity, type 2 diabetes mellitus (T2DM) or clinical evidence of

Fig. 1 Recommended algorithm to diagnose, evaluate, and monitor disease severity in suspected patients with MAFLD and management approach for confirmed cases. *HDL-C* high-density lipoprotein (HDL) cholesterol; *APRI* aspartate aminotransferase (AST)-to-platelet ratio index, *FIB-4* Fibrosis-4 index, *NFS* MAFLD fibrosis score; *ELF* enhanced liver fibrosis; *ADAPT* A PRO-C3-based fibrosis algorithm that included age, presence of diabetes, *PRO-C3* and platelet count, *SSI*, supersonic shear imaging; *AFRI* acoustic radiation force impulse; *VCTE* vibration-controlled transient elastography; *MRE* magnetic resonance elastography. Individuals can be defined as having low, intermediate, or high risk for advanced fibrosis for each score as per the following cut-offs: *APRI* (0.5 and 1.5), *FIB-4* (1.30 and 2.67),, *NFS* (lower cutoff < -1.455 and > 0.67611)



metabolic dysfunction, such as an increased waist circumference and an abnormal lipid or glycemic profile. Situations including cirrhosis cases where liver fat is no longer present are recognized as a special category within the new criteria. A recent study on a cohort of 13,083 patients from the NHANES III (National Health and Nutrition Examination Surveys) database showed that the MAFLD criteria are more practical and have higher ability for identifying at-high risk patients than the previous NAFLD criteria [30].

Diagnosis and impact of MAFLD in the setting of other liver disease

Since MAFLD is no longer a diagnosis of exclusion and is based on the presence of metabolic dysfunction, it is now possible to diagnose its coexistence with other liver diseases such as alcoholic liver disease (ALD), chronic hepatitis B virus infection (CHB), and chronic hepatitis C virus infection (CHC), primary biliary cholangitis, and primary hemochromatosis, especially in Asian populations. Moreover, meeting the criteria for a diagnosis of MAFLD plus one and more other less frequent causes of fatty liver

Table 2 Etiology of fatty liver disease

Etiology classification	Specific causes
Metabolic associated fatty liver disease	Overweight/obese, type 2 diabetes mellitus, metabolically unhealthy normal weight subjects
Alcohol associated fatty liver disease	Significant alcohol consumption (> 21 standard drinks per week in men and > 14 standard drinks per week in women over a 2-year period), binge drinking (> 5 standard drinks in men and > 4 standard drinks in women over a 2-h period), and lifetime alcohol intake > 100 kg [31]
Alternative causes of fatty liver disease	Long-term use of steatogenic medications (corticosteroids, valproic acid, tamoxifen, methotrexate, amiodarone, etc.), exposure to some chemicals, HCV genotype 3 infection, Wilson's disease, coeliac disease, starvation, total parenteral nutrition, severe surgical weight loss, disorders of lipid metabolism (abetalipoproteinemia, hypobeta lipoproteinemia, lysosomal acid lipase deficiency, familial combined hyperlipidaemia, lipodystrophy and Mauriac syndrome), Weber-Christian syndrome, glycogen storage disease, Cushing's syndrome, etc

either at baseline or at follow-up, e.g., long-term use of steatogenic medications, HCV genotype 3 infection, or Wilson disease should also be diagnosed as mixed or dual etiology liver disease as the case may be (Table 2).

These individuals likely have a different natural history and response to therapy than those with liver disease of a “single” etiology [29]. Notably, MAFLD may accelerate the progression of liver disease in patients with ALD and CHB, and synergistically induce liver cirrhosis or even HCC development [32, 33]. Therefore, patients with MAFLD should be carefully evaluated for possible concurrent liver diseases such as ALD and viral hepatitis. Conversely, MAFLD and underlying metabolic dysfunction may increase the risk of metabolic and cardiovascular events in patients with other liver diseases.

MAFLD patients with ALD represent a large and important group that requires further investigation and

characterisation with respect to natural history, outcomes and response to treatment. Meticulous history taking for lifetime and current alcohol intake through patient interview aid in diagnosis of dual etiology fatty liver disease. Recently, there has been mounting evidence against the so-called “safe limits” for alcohol intake in the setting of MAFLD [28, 34, 35], as even low alcohol intake is associated with an increased risk for cirrhosis and cancer, and decreased rates of improvement in steatohepatitis [28, 36, 37]. The effect of alcohol intake on the progression of liver disease and outcomes likely has a dose-response with a synergistic negative effect in the presence of metabolic syndrome and the “cut-off” values of alcohol intake in MAFLD should be set lower than the apparent “threshold levels”. Therefore, patients with MAFLD should be advised to avoid alcohol and if that is not possible, to consume the lowest amount possible.

Table 3 Risk factors for MAFLD

Major risk factor	Common and uncommon risk factor
Overweight/obesity	Gut microbiota
Central obesity	Hyperuricemia
Type 2 diabetes mellitus	Hypothyroidism
Dyslipidemia	Sleep apnoea syndrome
Arterial hypertension	Polycystic ovary syndrome
Metabolic syndrome	Polycythaemia
Insulin resistance	Hypopituitarism
Dietary factors: high-calorie diets rich in saturated fats and cholesterol, soft drinks high in fructose, highly processed foods	Genetic variations: <i>PNPLA3</i> , <i>TM6SF2</i> , <i>GCKR</i> , <i>MBOAT7</i> , and <i>HSD17B13</i>
Sedentary lifestyle or sedentary occupation, low level of physical activity	Epigenetic factors: microRNAs (miR), DNA methylation, histone modification, and ubiquitination alterations
Sarcopenia	A personal or family history of T2DM, premature vascular disease, atherogenic dyslipidemia and high blood pressure (metabolic syndrome), fatty liver

Notably, many of these factors could be association, it is hard to ascertain the causality

PNPLA3 patatin-like phospholipase domain-containing protein 3; *TM6SF2* transmembrane 6 superfamily member 2, *GCKR* glucokinase regulator, *MBOAT7* membrane bound O-acyltransferase domain containing 7 *HSD17B13*: hydroxysteroid 17-beta dehydrogenase-13

With the high prevalence rates of MAFLD and CHC, it is expected that these two disease entities will occur together and their concomitant existence is estimated to be approximately 38% [38]. MAFLD significantly impacts the entire natural course of CHC including progression of the liver disease, therapeutic responses, and the development of some extrahepatic complications [39–44]. Viral eradication by direct-acting anti-viral therapy or previously by interferon therapy was demonstrated to reduce insulin resistance, liver steatosis, and fibrosis in patients with CHC, especially in genotype 3 HCV infection [45, 46].

Although CHB infection is negatively associated with hepatic steatosis in some reports [47], the number of patients with coexisting CHB and MAFLD is growing rapidly [48]. Notably, MAFLD may accelerate the progression of liver disease in patients with CHB; a recent study from Thailand suggested that MAFLD was independently associated with increased risk of significant liver fibrosis (OR, 10.0; 95% CI 2.08–48.5) and advanced liver fibrosis (OR, 3.45; 95% CI 1.11–10.7) in CHB patients [49]. Similarly, another study demonstrated that MAFLD independently increased the risk of HCC development by 7.3-fold (OR: 7.3, 95%CI 1.52–34.76) in patients with CHB [50].

MAFLD is becoming a major reason for persistently abnormal liver tests and poor outcomes in individuals with CHB and/or CHC infection after profound virological suppression or sustained virological response [51, 52]. Treatment of MAFLD in this group should be considered as for non-infected patients.

Should MAFLD be considered with other liver diseases?

Recommendations

- MAFLD can and frequently does coexist with other liver diseases (A1).
- MAFLD treatment and that of concomitant diseases should be as per the recommendations for each of the diseases (B1).

Table 4 Working definition of overweight/obesity and central obesity for Asian adults

Lean (normal range): BMI 18.5–22.9 kg/m²

Overweight: BMI 23.0–24.9 kg/m²

Obesity: BMI > 25.0 kg/m²

Central obesity: Waist circumference (measured at the top of the iliac crest) > 90 cm for males and > 80 cm for females

BMI body mass index

Risk factors for MAFLD

MAFLD is a public health challenge in many parts of Asia-Pacific region due to socioeconomic changes and the rapid transition from undernutrition to overnutrition. In turn, excess energy intake relative to expenditure with nutritionally imbalanced and unhealthy diets contribute to an accumulation of triglyceride in adipose tissue and the liver. Risk factors for MAFLD in Asians are similar to that in Westerners (Table 3). However, Asians are more likely to have central fat deposition despite having a lower body mass index (BMI). In detailed metabolic studies, south Asians in the USA had higher insulin resistance (IR) compared to Caucasians in spite of having an equal or lower BMI [53]. Likewise, Asian-Indian men have greater liver fat content and higher IR than age- and BMI-matched European individuals [54, 55]. A greater waist circumference and visceral adipose tissue (VAT) has a more significant correlation with IR and MAFLD than a high BMI [56, 57]. Similarly, abdominal and visceral adiposity is greater among Asians compared with Caucasians and lower in Africans, for the same BMI [58–61]. Modified cut-off points for BMI and waist circumference have thus been recommended for the Asian population [62, 63] (Table 4). Consistent with this phenotype, rates of T2DM are also markedly increased in Asian Indian populations [6, 64]. Even, non-obese and lean Asian people with MAFLD are at a high risk of metabolic syndrome and T2DM [65].

Although overweight/obesity is closely associated with the development and progression of MAFLD, subtle weight gain that has not led to overweight is an important determinant of incident metabolic disease and MAFLD. Within the MAFLD population, 19.2% of people are lean and 40.8% are non-obese, without differences in the histological severity of disease between lean and obese patients [66, 67]. Up to one-third of patients with MAFLD and a normal BMI meet the criteria for metabolic syndrome [67].

Metabolic syndrome and its components also increase the risk of developing MAFLD. As would be expected from these data, the global prevalence of MAFLD among patients with T2DM is 55.5% and up to 10–20% have advanced fibrosis [68]. The bidirectional causal relationship of components of metabolic syndrome with MAFLD has been well established [69]. Thus, patients with MAFLD benefit from lifestyle intervention and weight loss [70] as well as assessment for, and treatment of, other components of the metabolic syndrome. Such an approach will reduce the risk of liver and non-liver related comorbidities, while screening for MAFLD by ultrasonography should be considered in at-risk populations including those with overweight/obesity, T2DM or metabolic syndrome.

A functional role for microbiota in MAFLD-pathogenesis is increasingly appreciated [71]. This is best illustrated by

differences in the impact of gut bacteria from obese and lean humans on the risk of fat accumulation in germ-free mice. Transplantation of fecal bacteria from obese adult humans led to a higher percentage of body fat in the mice compared to those from lean adults [72]. However, human data on the role of gut microbiota in MAFLD and its therapeutic use are in their early stage.

There is strong evidence in support of racial and socio-economic-disparity-based differences in gut microbiota. In humans, greater fecal bacterial diversity is seen in less affluent populations such as those from Bangladesh, when compared to urbanized European or American children [73]. Similarly, greater fecal bacterial diversity was noted in children from rural South Thailand compared to urbanized children from Singapore [74]. This diversity is obvious even within ethnic groups with a relatively narrow range of socio-economic discrepancy. For example, a recent study compared pre-adolescents from three distinct Malaysian ethnic groups [Malays, Chinese and Orang Asli (indigenous)], with a relatively narrow range of socioeconomic discrepancy. The study demonstrated that the highest bacterial diversity was in indigenous children who are relatively economically deprived compared to their Chinese counterparts [75].

The role of factors such as genetics, epigenetics, and sarcopenia have also been recognized and are the subject of recent reviews [76–79]. Incorporation of genetic variant testing in routine clinical practice is not recommended currently due to the lack of certainty on cost-effectiveness and utility.

Should the high-risk population be screened for MAFLD?

Recommendations

- Screening for MAFLD by ultrasonography should be considered in at-risk populations such as patients with overweight/obesity, T2DM and metabolic syndrome (A1).
- Patients with MAFLD should be assessed for other components of metabolic syndrome and be treated accordingly (A1).
- Patients with MAFLD should receive advice and support for lifestyle interventions to reduce the risk of events from metabolic and cardiovascular disease, and to resolve fatty liver disease (A1).

Natural history of MAFLD

Globally, 54.3% of deaths due to cirrhosis and 72.7% of deaths due to hepatocellular carcinoma (HCC) occurred in the Asia-Pacific region in 2015[1]. However, the true burden of MAFLD in Asia is not fully understood. Cardiovascular disease

(CVD) followed by cancer and liver failure are the main causes of death in MAFLD. There is clear evidence for ethnic differences in prevalence of MAFLD, with highest prevalence among Latinos and least among African Americans, with Caucasian and Asian ethnicities having an intermediate prevalence [80–82]. In contrast, less is known regarding the consequences of hepatic steatosis, liver inflammation, and fibrosis according to ethnicity. While data are scant, cross-sectional studies suggested that Asian subjects are more likely to have worse histologic injury. In a recent study, despite having a lower BMI than other groups, Asians (included patients of Korean, Filipino, Chinese and Indian origin) had more lobular inflammation and higher grades of ballooning compared to other ethnicities (Caucasian, Hispanics and African Americans) [80]. In another report, Asians living in the US showed a trend toward an association with more severe steatosis and inflammation compared to Caucasians [83]. If liver tests are used as a surrogate for hepatic inflammation, a large cross-sectional multiethnic cohort from the United Kingdom suggested that the highest prevalence of abnormal liver tests is among Asians (Bangladeshi (18.4%), Pakistani (17.6%), and Indian (14.8%)), compared with Caucasians (13.5%), Africans (11.8%), and Caribbean islanders (10.2%). In a subsequent multivariate analysis, Bangladeshi ethnicity was an independent risk factor for MAFLD and for elevated liver tests [84]. Similarly, scant data are available regarding liver fibrosis. Asians tended to have a higher risk for fibrosis, while Africans were at lower risk compared to Caucasians. This, however, did not reach statistical significance possibly due to sample size limitations [80, 83]. Notably, these biopsy-based studies might be subject to selection bias. A population-based study in Hong Kong suggested that while MAFLD is prevalent and detected in about 25% of the population, the prevalence of advanced fibrosis is low [85].

In the Asia-Pacific region there is a paucity of data on MAFLD-HCC and is likely confounded by the higher prevalence of viral hepatitis, a major risk factor for HCC in Asia. Viral hepatitis increases the risk of oncogenic transformation, viral hepatitis can also contribute to HCC development even in the absence of serological clues of previous infection [86], which is most likely to occur in the context of CHB [86].

The available data suggest that 2% of all HCC in Japan was due to MAFLD; the median age of patients was 72 years, and 62% were males [87]. Similarly, a large retrospective cohort study of 6,508 Japanese with MAFLD suggested that the rate of new HCC was 0.043% during a median follow-up of 5.6 years. In this study, 184 patients with significant fibrosis were identified using the AST-to-platelet ratio index; 6/184 (3.26%) developed HCC during the follow-up period [88]. Similar trends have been noted from other countries in Asia. In South Korea, a study of 329 patients has shown that the proportion with MAFLD-related HCC rose from 3.8% in 2001–2005 to 12.2% in 2006–2010; by contrast, HBV-related HCC declined from

86.6% to 67.4% [89]. In India, despite the high prevalence of MAFLD and T2DM, there is a lack of data on the prevalence of MAFLD-HCC. A recent estimate suggested that a potential staggering 930,000 people in India might have MAFLD-HCC [90].

Notably, in a recent modelling study of eight countries, the MAFLD population in China is projected to increase by 29.1% to 314.58 million cases from 2016 to 2030 [91]. Decompensated cirrhosis and liver-related deaths secondary to MAFLD are expected to double during the same period. Similarly, in another study looking at fibrosis progression among the MAFLD populations of Hong Kong, Singapore, South Korea and Taiwan [92]. Prevalent MAFLD cases were projected to increase from 6 to 20%, incident decompensated cirrhosis from 65 to 100% and incident cases of HCC from 65 to 85%, over the period 2019–2030.

In regard to comparisons with other liver diseases, in a prospective cohort study, the yearly cumulative incidence of HCC was 2.6% in MAFLD-cirrhosis during a median follow-up of 3.2 years. This was comparable with a reported 4% incidence in a CHC cirrhotic population over the same time period [93]. A recent multicentre study suggested that MAFLD-HCC is more often detected at a later tumor stage compared to HCV-HCC, and could arise in the absence of cirrhosis with a similar survival rate compared to HCV infection, after patient matching [94]. Another prospective cohort multi-centre study from Australia, the US, and Europe reported that patients with MAFLD and advanced fibrosis have lower rates of HCC and liver-related complications compared to those with HCV infection, but similar overall mortality [95]. Large prospective studies from Asia are required to corroborate these data.

Overall, these figures are likely to be underestimated as a significant number will have had dual etiology liver disease with MAFLD and viral hepatitis or ALD but would have been identified as viral hepatitis- or ALD-associated HCC. In addition, another important consideration is that the prevalence figures of MAFLD-HCC may be an underestimate if cryptogenic cirrhosis attributable to MAFLD is considered. In a recent study of 105 patients with HCC, 29% were found to have cryptogenic cirrhosis; half of these had histological or clinical features consistent with MAFLD [96]. Similar observations have been reported from Asia. In a Japanese report, clinical features of MAFLD were more frequent in cryptogenic cirrhosis than with virus-related cirrhosis [97], while in India, two thirds of patients with a pre-transplant diagnosis of cryptogenic cirrhosis were ultimately diagnosed with MAFLD on their explants [98]. Thus, with current recommendations for abandoning the term “cryptogenic cirrhosis” to describe cirrhotic patients with low or undetectable levels of steatosis but who meet the diagnostic criteria for

MAFLD, many would fit under the umbrella of “MAFLD-related cirrhosis” [99].

Extrahepatic manifestations of MAFLD

MAFLD is one aspect of a multi-system disease and it is therefore not surprising that cardiovascular disease (CVD) is its most important complication, followed by cancer and others diseases including obstructive sleep apnea, chronic kidney disease (CKD), polycystic ovarian syndrome, and osteoporosis.

MAFLD is associated with subclinical atherosclerosis as evidenced by increased carotid intima media thickness, coronary artery calcification score, arterial stiffness, and endothelial dysfunction [100]. In a longitudinal study of 8020 subjects without subclinical carotid atherosclerosis at baseline, those with regression of MAFLD were less likely to develop subclinical carotid atherosclerosis compared to those with persistent MAFLD. Furthermore, the risk of developing subclinical carotid atherosclerosis was higher among subjects with more severe liver fibrosis [101]. Importantly, MAFLD is associated with an increased risk of fatal and/or non-fatal cardiovascular events and the risk is higher among patients with more severe liver disease [102, 103]. Furthermore, those with more severe fatty liver disease had a higher in-hospital and 3-year mortality following an episode of myocardial infarction [104]. Overall, CVD is the leading cause of mortality in patients with MAFLD and baseline liver fibrosis is the strongest predictor [105]. Therefore, patients with MAFLD should be evaluated for CVD risk.

Francque et al., have proposed an algorithm for screening MAFLD patients for cardiovascular disease. MAFLD patients with clinically active CVD or a history of a cardiovascular event should be under the care of a cardiologist. Otherwise, patients with more severe disease (i.e. steatohepatitis or significant fibrosis), T2DM, or increased risk of CVD should undergo further evaluation (e.g. electrocardiogram, echocardiogram and/or subclinical CVD screening, where available) and be considered for referral to a cardiologist. Patients who are negative on further evaluation can be re-evaluated every 2–3 years [106]. CVD risk can be estimated using risk scores (e.g. Atherosclerotic Cardiovascular Disease Risk Estimator Plus, available at <https://tools.acc.org/ASCVD-Risk-Estimator-Plus/#/content/about/>).

Similarly, a strong association between MAFLD and CKD has been established, independent of the presence of potential confounding factors such as obesity, T2DM, and hypertension [107]. An independent association between MAFLD and sarcopenia has also been suggested.

Dyslipidemia, if present, should be treated to reduce the risk of cardiovascular events and mortality. A study on 428 MAFLD patients across four Asian countries found disproportionately low statin use compared with the prevalence

of dyslipidemia; 59% of patients who were not on a statin should have been on one, while the majority (74%) of patients who were on a statin were not treated to target [108]. A post hoc analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation study found statin therapy to not only be safe but it resulted in improved liver tests and reduced cardiovascular morbidity in patients with mild to moderately abnormal liver tests, likely due to MAFLD [109].

A blood pressure target of $<130/80$ mmHg is appropriate for most patients and HbA1c level of $\leq 6.5\%$ is considered optimal if it can be achieved in a safe and cost-effective manner [110]. The types and choice of medications for treatment of dyslipidemia, hypertension, and T2DM are beyond the scope of this paper. However, newer medications for T2DM, i.e. glucagon-like peptide-1 analogue (GLP-1a) and sodium glucose cotransporter 2 inhibitors (SGLT2i) have been shown to improve metabolic syndrome and cardiovascular outcomes and may be useful for treatment of steatohepatitis. Empagliflozin, for example, significantly reduced overall and cardiovascular-specific mortality and hospitalization for heart failure compared with placebo [111]. Likewise, liraglutide significantly reduces death from cerebro-cardiovascular causes compared with placebo [112]. Risk factor modification to target is typically undertaken in primary care; however, specialists treating patients with MAFLD should be encouraged to assess and undertake risk factor management as part of a holistic approach to patient care.

How to manage the extra-hepatic manifestations of MAFLD?

Recommendations

- MAFLD patients should be evaluated for cardiovascular disease and cardiovascular risk, and referred to a cardiologist, if necessary (A1).
- Dyslipidemia, hypertension, and diabetes mellitus should be identified and treated accordingly to reduce the risk of cardiovascular and kidney disease (A1).

Non-invasive tests

The purpose of non-invasive tests (NITs) includes establishing a diagnosis of MAFLD, assessing disease severity, and monitoring disease progression and treatment response [113]. The detection of hepatic steatosis by histology or imaging is key to a diagnosis of MAFLD. In clinical practice, routine imaging such as abdominal ultrasonography is usually sufficient for the detection of hepatic steatosis [114]. Controlled attenuation parameter (CAP) measurement by vibration-controlled transient elastography (VCTE) is more sensitive than ultrasonography [115]. As a continuous

variable it can theoretically be used to monitor changes in hepatic steatosis over time, though this needs to be confirmed by studies using paired liver biopsies or other quantifiable methods for assessing steatosis such as with MRS or MRI proton density fat fraction (MRI-PDFF). An interquartile range $> 30\text{--}40$ dB/m has been associated with less reliable CAP measurements [116, 117] but its role requires further validation.

MRI-based techniques such as MRI-PDFF and proton-MRS are considered the gold standard to quantify liver fat. In some clinical trials, a $> 30\%$ relative reduction in liver fat fraction correlated with histological improvements in the activity score or resolution of steatohepatitis [118], though the same has not been reported in other studies [119], and the association is probably drug-specific. Currently, liver fat fraction by MRI is often used in early phase clinical trials to determine potential benefits of the investigational drug treatment.

The fatty liver index (FLI) is a simple algorithm based on BMI, waist circumference, triglycerides, and GGT for detecting fatty liver and may be used as an alternative method for the diagnosis of steatosis, particularly in large population studies [120]. Ultrasonographic Fatty Liver Indicator (US -FLI) is another scoring system used to rule out steatohepatitis. The score ranges from 2 to 8 based on ultrasonographic features, including the intensity of liver/kidney contrast [121].

Among the various histological features of MAFLD, the degree of liver fibrosis has the strongest correlation with future liver-related morbidity and mortality [122]. NITs of fibrosis can be classified into simple fibrosis scores, specific fibrosis biomarkers, and imaging biomarkers [123]. Simple fibrosis scores such as the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) [124], Fibrosis-4 index (FIB-4) [125], and NAFLD fibrosis score (NFS) [126] only involve clinical and routine laboratory parameters and are inexpensive. Although the accuracy is modest, these scores have good negative predictive values to exclude advanced fibrosis and is the primary clinical utility of these scores [127, 128]. This is particularly important in primary care or resource poor settings where the pre-test probability of advanced fibrosis is low [129]. Individuals can be defined as being at low, intermediate, or high risk for advanced fibrosis for each score according to the following cut-offs: APRI (0.5 and 1.5), FIB-4 (1.30 and 2.67), NFS (<-1.455 and >0.67611). People with low fibrosis scores are also at low risk of developing hepatic complications [130]. Therefore, it is reasonable to use simple fibrosis scores as an initial assessment in primary care. A limitation of these scores is that they incorporate liver enzymes in the models. As patients with liver enzymes in the normal range can have the full spectrum of liver fibrosis stages, it remains a shortcoming. Furthermore, liver enzymes are sensitive to age, which can lead to false positive results [131].

In contrast, more specific fibrosis markers are needed in specialist settings to guide the management of patients [132, 133]. Among them, the enhanced liver fibrosis panel has been tested in multiple observational studies and clinical trials with good overall accuracy [134]. Another biomarker, called Pro-C3, reflects the formation of type III collagen in hepatocytes. The ADAPT algorithm includes age, T2DM, Pro-C3, and platelet count and has an area under the receiver-operating characteristics curve of 0.87 for advanced fibrosis [135].

Liver stiffness measurement (LSM) by VCTE is widely used in the Asia-Pacific region, in part because of patient preference against biopsy. Although the success rate of VCTE is lower in obese subjects, the majority of MAFLD patients can achieve successful liver stiffness measurement with the XL probe [136, 137], and the same cut-offs can be used for both the M and XL probes if the probes are used according to the body habitus or guided by the automated probe selection tool [138]. The diagnostic performance for advanced hepatic fibrosis of shear wave elastography is similar to that of VCTE [139]. Although the quality criteria for fibrosis assessment is limited, shear wave elastography is an option for liver stiffness measurement.

Non-obese MAFLD is more often described in Asia; commonly used fibrosis tests do not appear to be affected in this special group [140]. The combination of LSM and simple fibrosis scores has the advantage of improving the positive predictive value and reducing the proportion of patients with indeterminate results [141]. In head-to-head comparisons, magnetic resonance elastography has higher success rates and an even higher accuracy than VCTE, but its wider application is limited by cost and availability [142, 143].

On the other hand, there has not been any robust biomarker for steatohepatitis. Their development is in part limited by the substantial intra-and inter-observer variability in the assessment of histological lobular inflammation and hepatocyte ballooning and the fact that inflammation can resolve even over relatively short periods. Serum keratin-18 fragments (also known as cytokeratin-18 fragments) reflect hepatocyte apoptosis and were proposed as a steatohepatitis biomarker. However, subsequent studies suggested that its overall accuracy is modest [144]. In a recent multi-centre study, the combination of AST with CAP and liver stiffness measurement by VCTE (the FAST score) achieved a c-statistic of 0.74–0.95 for the detection of fibrotic steatohepatitis (NAS score ≥ 4 and fibrosis score ≥ 2) [145].

How and what non-invasive scores to use in MAFLD?

- Abdominal ultrasonography is the recommended first-line diagnostic modality for imaging of MAFLD and is usually sufficient for the detection of hepatic steatosis (A1).

- If available, controlled attenuation parameter (CAP) measurement by vibration-controlled transient elastography (VCTE) may be used as a more sensitive tool than ultrasonography. If imaging modalities are not available or feasible such as in very large epidemiological studies, serum biomarkers and scores such as the fatty liver index (FLI) may be used as an alternative method for the diagnosis of steatosis (B2).
- Magnetic resonance imaging-based techniques such as MRI-PDFF and proton-MRS are considered the gold standard to quantify liver fat but it is not recommended for routine clinical practice useful tool in early phase clinical trials (A1).
- There is no robust biomarker for steatohepatitis and liver biopsy remains the test of choice for assessment of steatohepatitis (A1).
- The exclusion of high risk of significant or advanced fibrosis is acceptable using non-invasive tools, liver stiffness measurement by VCTE or shear wave elastography and blood biomarkers and scores of fibrosis or their sequential combination (A2).
- The confirmation of significant or advanced fibrosis by liver stiffness measurement and/or serum biomarkers/scores is less accurate and would require further confirmation by liver biopsy as per the clinical context (B2).

Liver biopsy

With the development of NITs of hepatic steatosis and fibrosis, routine liver biopsy to assess the severity of MAFLD cannot be justified. However, liver biopsy remains an important diagnostic test to rule out other liver diseases, especially when the clinical picture is atypical. Some examples of atypical features include very high aminotransferase level and the presence of severe hepatic steatosis in patients with no or little metabolic burden. Although non-invasive tests are sufficient to guide clinical management in the majority, some cases may fall into the grey zone when dual cut-offs are used (i.e. low cut-off to rule out and high cut-off to rule in a certain fibrosis stage) [141], and others may have unreliable results (e.g. high interquartile range-to-median ratio in case of liver stiffness measurement) [146]. In some patients, NITs results may not fit the clinical picture (e.g. normal fibrosis tests in patients with radiological features of cirrhosis and/or thrombocytopenia). Liver biopsy can be performed in such instances to clarify the situation.

MAFLD is common in patients with gallstones and morbid obesity [147, 148]. Because liver biopsy during laparoscopic or open surgery is safe, it is reasonable to offer this procedure in patients at risk of MAFLD.

Table 5 Comparisons of grading and staging of histological lesions in MAFLD

	Brunt et al.	Kleiner et al.	Bedossa et al.
Steatosis	0: None 1: Up to 33% 2: 33–66% 3: > 66%	0: < 5% 1: 5–33% 2: 33–66% 3: > 66%	0: < 5% 1: 5%–33% 2: 34–66% 3: > 67%
Lobular inflammation	0: None 1: 1–2 foci per 20× 2: Up to 4 foci per 20× 3: > 4 foci per 20×	0: No foci 1: < 2 foci per 20× 2: 2–4 foci per 20× 3: > 4 foci per 20×	0: None 1: ≤ 2 foci per 20× 2: > 2 foci per 20×
Portal inflammation was graded as follows:	0: None 1: Mild 2: Moderate 3: Severe		
Hepatocyte ballooning	Mild Marked	0: None 1: Few 2: Many	0: Normal hepatocytes with cuboidal shape and pink eosinophilic cytoplasm 1: Presence of clusters of hepatocytes with a rounded shape and pale cytoplasm usually reticulated; although shape is different, size is quite similar to that of normal hepatocytes 2: Same as grade 1 with some enlarged hepatocytes, at least two that of normal cells
Fibrosis	0: None 1: Perisinusoidal 2: Perisinusoidal and periportal 3: Bridging 4: Cirrhosis	0: None 1a: Delicate perisinusoidal 1b: Dense perisinusoidal 1c: Portal only 2: Perisinusoidal and periportal 3: Bridging 4: Cirrhosis	0: None 1a: Delicate perisinusoidal 1b: Dense perisinusoidal 1c: Portal only 2: Perisinusoidal and periportal 3: Bridging 4: Cirrhosis

Finally, resolution of steatohepatitis and improvement in fibrosis remain key surrogate endpoints in phase 2b/3 MAFLD trials. Achieving these short-term histological endpoints may allow drug approval under the United States Food and Drug Administration (FDA)'s subpart H pathway [149]. Besides, liver biopsy is an important tool to enhance our understanding of MAFLD through not only careful histological assessment but also molecular and “omic” tools.

When would liver biopsy be indicated in MAFLD?

Recommendations: Indications for liver biopsy in patients with suspected MAFLD (A1)

- Uncertain diagnosis and evaluation for dual etiologies.
- Non-invasive tests showing indeterminate or non-concordant results.
- During cholecystectomy and bariatric surgery.
- Approved research

Pathological recommendations

The term non-alcoholic steatohepatitis (NASH) was coined by Ludwig et al. to describe a cohort of patients with a liver disease that histologically mimicked alcoholic steatohepatitis in patients without a history of significant alcohol intake and has been in use [150] till recently [29].

The minimum required staining includes hematoxylin and eosin (for detection of morphological features), picrosirius red or Mallory's stain (for the detection of fibrosis), and Perl's staining (for the detection of hemosiderosis). Whenever possible and ethically approved, the storage of non-processed fresh frozen tissue for other kinds of staining such as lipid staining and research is advisable. Grading and staging of histological lesions in steatohepatitis was first proposed by Brunt et al. Necroinflammation was graded as mild, moderate, or severe, based on the combination of steatosis, lobular and portal inflammation, and hepatocyte ballooning (Table 5) [151]. In 2005, Kleiner et al. developed and validated a histological evaluation system that encompassed

the spectrum of MAFLD and allowed for assessment of changes with therapy for the NASH Clinical Research Network (Table 5). The activity score (NAS) included only features of active injury and that are potentially reversible in the short term. The NAS was defined as the unweighted sum of scores for steatosis, lobular inflammation, and ballooning. Cases with NAS of 0 to 2 were largely considered not-NASH, while most cases with scores ≥ 5 were diagnosed as NASH. Cases with scores of 3 and 4 were divided almost evenly between the three diagnostic categories of NASH, borderline, and not-NASH. Importantly, the authors noted that the primary purpose of the NAS was to assess overall histological change and numeric values were not intended to replace the pathologist's diagnosis of steatohepatitis [152].

In 2012, Bedossa et al. developed and validated an algorithm for categorization (subsequently called the fatty liver inhibition of progression or FLIP algorithm) and scoring (called the SAF score) for MAFLD (Table 5). NAFLD (now MAFLD) was defined as the presence of steatosis in $> 5\%$ of hepatocytes and NASH by the addition of hepatocyte ballooning and lobular inflammation of any degree. The SAF score summarized the main histological lesions. Lobular inflammation was graded 0–2, unlike the NAS which graded lobular inflammation 0 to 3. However, grade 2 of the SAF score does encompass grade 2 and 3 of the NAS. The authors also noted that they did not change the definition of hepatocyte ballooning proposed by the NASH CRN, but added reference to the size and shape of hepatocytes for clarity. The activity score was the unweighted sum of lobular inflammation and hepatocyte ballooning. Among the 204 patients with NAS 3 to 4, 116 (57%) had no steatohepatitis, whereas 88 (43%) had steatohepatitis. On the other hand, among the 249 patients with A ≥ 2 , 230 (92%) had steatohepatitis, whereas all patients with A < 2 did not have steatohepatitis. Furthermore, there was a strong correlation between activity score and the serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. In other words, the activity score provided a more robust histological approach that clearly distinguished most patients with steatohepatitis and associated with transaminase levels. Moreover, the authors found no significant differences in ALT and AST levels between patients with normal liver and patients with pure steatosis supporting the exclusion of steatosis as a marker of activity [153]. The NASH CRN system and FLIP algorithm and SAF score improved interobserver variability [154] and has been validated clinically [152, 155]. Further studies are needed to determine how the NAS relates to the SAF score. This will have important implications, particularly for studies of the natural history of MAFLD using previous histological data.

What is the recommended pathological reporting?

Recommendations

- A standardized reporting of histological lesions in MAFLD patients is important for the study of natural history, enrolment in clinical trials, and evaluation of response to treatment and comparison of data from different geographic locations (A1).
- Histological evaluation should include at least hematoxylin and eosin stains, and either Masson's trichrome stain or picrosirius red stain (A1).
- Reporting should be standardised using either the FLIP algorithm and SAF score or the NASH CRN system for reporting of histological lesions in MAFLD (B1).

MAFLD-related cirrhosis

At the outset, patients with cirrhosis, even if they are without significant hepatic steatosis, but meet the diagnostic criteria for MAFLD, should be considered as having MAFLD-related cirrhosis. This is because multiple lines of evidence indicate that hepatic steatosis may diminish with progression to cirrhosis [156]. Equally important is that there is a substantial proportion of MAFLD patients with cirrhosis who were previously undiagnosed and present for the first time with decompensated cirrhosis, variceal bleeding, or HCC.

Cirrhosis can be diagnosed by typical findings on ultrasonography, but the diagnosis may be missed when this is obscured by liver fat. In this sense, assessment of MAFLD patients beyond ultrasonography is necessary. LSM provides a reliable assessment of the severity of liver fibrosis and can be used to diagnose cirrhosis in MAFLD patients in the correct clinical context [157].

Liver fibrosis is the most important predictor of mortality in MAFLD patients, with the highest risk among those with cirrhosis [158]. The spectrum from severe fibrosis to cirrhosis is a continuum in asymptomatic patients and distinguishing the two is often not possible on clinical grounds. Hence, the term "compensated advanced chronic liver disease" has been introduced. LSM < 10 kPa in the absence of other known clinical signs rules out, whereas a LSM of 10–15 kPa is suggestive, and > 15 kPa is highly suggestive of compensated advanced chronic liver disease [159]. As mentioned previously, the same LSM cut-offs can be used with the M probe or XL probe when probe choice is based on a computer recommendation or BMI [138].

MAFLD patients with liver stiffness measurement > 15 kPa should be considered for surveillance for HCC [138], whereas those with LSM > 20 –25 kPa and/or thrombocytopenia are likely to have clinically significant portal hypertension and should undergo endoscopy for

variceal screening [159]. LSM is also useful for prognostication in patients with MAFLD, with mortality rate being higher with increasing LSM [160]. LSM may not be readily available in many places. In such settings, fibrosis scores can be a first step to identify patients who are more likely to have severe liver fibrosis and for referral for LSM [161]. It is unclear whether MAFLD cirrhotics should be biopsied for activity assessment and further studies would be required to clarify this aspect.

How to diagnose MAFLD-cirrhosis?

Recommendations

- Patients with cirrhosis in the absence of typical histology who meet the following criteria should be considered as having MAFLD-related cirrhosis:

Past or present evidence of metabolic risk factors that meet the criteria to diagnose MAFLD, as described in Fig. 1, with at least one of the following:

- (1) Documentation of MAFLD on a previous liver biopsy*.
- (2) Historical documentation of steatosis by hepatic imaging* (B2).

**History of past alcohol intake should be considered as patients may have dual disease etiology with alcohol use disorder*

Diagnosis and monitoring for clinically significant portal hypertension and varices

Classification of cirrhosis is based on prognostic staging: compensated and decompensated cirrhosis [162, 163]. Such classification depends on the presence or absence of clinically evident decompensating events such as ascites, variceal hemorrhage, encephalopathy, jaundice, or spontaneous bacterial peritonitis.

The initial sequelae of MAFLD-cirrhosis or liver cirrhosis in general is portal hypertension, which contributes to most of the complications seen in cirrhotic patients. In MAFLD, this process classically starts close to the central vein (zone 3), where lipid droplet formation is most active [164]. Therefore, correctly monitoring for the development of clinically significant portal hypertension, defined by hepatic venous pressure gradient (HVPG) of 10 mm Hg is important. The measurement of HVPG is considered the gold standard for

monitoring clinically significant portal hypertension and is superior to liver biopsy for predicting complications in MAFLD patients, though it is invasive. Ultrasound is a safe technique for detecting morphological abnormalities associated with cirrhosis and portal hypertension. The identification of porto-collateral circulation on ultrasound, computed tomography (CT), or MRI or the evidence of a reversal of flow within the portal system is a specific and indicative measure of clinically significant portal hypertension and is associated with variceal development and growth [165]. Therefore, periodic screening by imaging methods is recommended in these patients. Notably, though by definition all patients with gastroesophageal varices have significant portal hypertension, clinically significant portal hypertension is present in approximately 50%–60% of patients with cirrhosis but without gastroesophageal varices. [166–168].

The prognosis is worse in patients with cirrhosis and gastroesophageal varices compared to those without gastroesophageal varices. Therefore, patients with MAFLD-cirrhosis should be screened for gastroesophageal varices according to Baveno VI Criteria. [169] A recent meta-analysis of 30 studies (8469 participants) suggested that Baveno VI criteria have high diagnostic accuracy as a triage test for screening for high-risk varices and varices in patients with compensated advanced chronic liver disease (sensitivity: 0.90 (95% CI 0.85–0.93) [170]. The criteria have recently been validated in 224 Chinese patients with MAFLD related compensated cirrhosis [171].

Diagnosis of the existence and size of varices and the presence of red wale marks at esophagogastroduodenoscopy (EGD) is required before the treatment of varices. However, EGD and variceal treatment are invasive procedures associated with the risk of bleeding [172]. As a result, there has been research into noninvasive methods for determining the presence of high-risk varices (i.e. medium/large varices) in order to avoid using endoscopy as a screening tool. Currently, the use of noninvasive tests to diagnose gastroesophageal varices is not recommended as the discriminative accuracy is limited. However, the assessment of LSM by transient elastography is accepted as an accurate technique to rule out high-risk varices in patients with compensated cirrhosis as described in the previous section. Patients with $LSM < 20$ kPa and platelet count $> 150,000/\text{mm}^3$ have a very low probability (< 5%) of having high-risk varices [173]. The use of EGD can be avoided in these patients. Those with $LSM > 20–25$ kPa are considered to have clinically significant portal hypertension. In cirrhotic patients without clinically significant portal hypertension, or LSM value between 10–15 kPa, monitoring of its onset is needed, although data on the specific time interval for monitoring are lacking.

Screening for HCC

Though hepatic steatosis associates with “risk factors for HCC” such as obesity, T2DM, and metabolic dysfunction, in the absence of cirrhosis the risk of HCC is low [156, 174–176]. Therefore, till we have more validated prediction biomarkers or algorithms for non-cirrhotic patients at high risk of HCC, surveillance for HCC is only recommended in patients with MAFLD-related cirrhosis. Similarly, patients with LSM > 15 kPa should be considered for surveillance for HCC.

Ultrasound is useful for HCC surveillance from the perspective of the safety, availability, and cost-effectiveness [177–182]. However, its sensitivity for detection of early stage HCC is reported to be only 47% [183], and simultaneous measurement of serum biomarker such as AFP is recommended [183, 184]. In addition, contrast-enhanced ultrasonography has been reported to be useful for the early detection of HCC, but is not widely available [185, 186]. When the ultrasound quality is inadequate due to obesity or excessive gas in the alimentary tract, or when confirmation is required, CT or MRI may be utilised as a surveillance modality [177–182]. Recently, non-enhanced MRI has been reported to have higher screening efficacy for HCC than ultrasonography in high-risk patients [187]. However, the availability and high cost are unsolved issues.

A randomized controlled trial showed that there is no significant difference in the detection rate of early HCC and in prognosis, when surveillance intervals are 3- or 6-monthly. The Italian Liver Cancer (ITA.LI.CA) group has shown that a 6-month surveillance interval has better rates of early HCC detection and prognosis than a 12-month interval [188]. Furthermore, 3-monthly surveillance led to a higher number of unnecessary recall procedures. Thus, based on the tumor volume doubling-time of HCC [189], a 6-month screening interval is recommended.

Treatment

Ideally, an effective therapy should not only reduce steatosis and liver injury, but also improve the metabolic sequelae and cardiovascular risk that is intimately linked to MAFLD. Hence, lifestyle modification including dietary change, weight loss, and structured exercise intervention remains the first-line and cornerstone therapy for this condition.

Diet and lifestyle changes

Lifestyle intervention programmes and weight loss can achieve reductions in liver fat content, resolution of steatohepatitis and fibrosis and improve a patients’ quality of life in a dose-dependent manner. A recent study ($n=293$) showed an improvement in liver histology (steatohepatitis) in 58% of those achieving > 5% and in 90% of those achieving weight loss of > 10%, respectively; only the latter demonstrated an improvement in fibrosis

stage (in 45%) [190]. Similarly, studies in Asian populations support the dose-response effect of weight loss with a 7–10% weight loss target; ~40% of those with MAFLD have some improvement even with 3–5% weight reduction [191, 192].

The overall aim of lifestyle intervention should be for gradual weight loss (up to 1 kg/week) with a hypocaloric diet (500–1000 kcal deficit). There is no strong evidence to support a particular dietary approach for the resolution of MAFLD. A recent meta-analysis of controlled isocaloric feeding with constant dietary protein and varying ratios of carbohydrate to fat suggests that the differences are too small, implying that “a calorie is a calorie” [193].

Patients with MAFLD tend to consume energy-dense foods rich in sugar-sweetened beverages and saturated fat and cholesterol, but deficient in micronutrients found in fresh fruit, fibre, green vegetables, and omega-3 polyunsaturated fatty acids (n-3 PUFA) [194]. Therefore, dietary plans should encourage low-carbohydrate, low-fat, and Mediterranean-type diets. In particular, adopting a Mediterranean-type diet has been shown to reduce CVD as primary prevention [195] and aids in fat mobilization from specific fat depots including hepatic, cardiac, and pancreatic fat deposits [196]. Isocaloric diets that are high in animal or plant protein were recently demonstrated to reduce hepatic steatosis and inflammation in patients with T2DM [197]. However, the differences between these different diet protocols on long-term outcomes is questionable [198]. A systematic review and meta-analysis showed a significantly decreased risk of MAFLD and liver fibrosis among regular coffee drinkers [199].

Weight loss and more importantly sustaining this effect is challenging. A multidisciplinary approach to management is pivotal to ensure motivation and continued participation in intervention programmes. Increasing clinic visit frequency [200] and utilising an internet-based approach for lifestyle changes [201] have been suggested to maximize the efficacy of weight loss in patients with MAFLD. Therefore, collaboration between different stakeholders, including government/policy makers, physicians, patients association and researchers can effectively promote healthy lifestyles and benefit patients with MAFLD.

Exercise

The optimal exercise dose for hepatic benefit, including type, intensity, volume, and effect size without weight loss is still subject to debate. For the general adult population, physical activity guidelines recommend 30 min/day of moderate-intensity exercise for ≥ 5 days/week or a total of ≥ 150 min/week or vigorous-intensity exercise for ≥ 20 min/day on ≥ 3 days/week (≥ 75 min/week). Resistance exercise on 2–3 days/week and flexibility exercises > 2 days/week are also recommended [202]. Specific data in patients with MAFLD are relatively limited, while exercise intervention with histological improvement

overtime as the primary outcome is difficult to undertake. A recent systematic review and meta-analysis suggested that exercise can reduce hepatic steatosis independent of diet change [203]. Exercise and life style intervention were also found to be able to reduce liver stiffness [204], HCC [205], and portal hypertension in patients with cirrhosis and obesity [206]. A randomized clinical trial that included 220 individuals showed that both vigorous and moderate exercise were equally effective in reducing intrahepatic triglycerides and the effect appeared to be largely mediated by weight loss [207]. In another study of an occupational health screening program that included 233,676 subjects between 2002 and 2014, moderate-vigorous exercise was demonstrated to be beneficial in decreasing the risk of development of new fatty liver or improving resolution of existing fatty liver during 5 years' follow-up [208]. In another study, a dose-response relationship between exercise volume and reduction in hepatic steatosis was demonstrated with higher responses observed in individuals exercising over 250 min/week as compared to those exercising for less than 150 min/week [209]. A recent systematic review suggested that both aerobic and resistance exercise reduces hepatic steatosis equally in MAFLD, while resistance exercise does this with less energy consumption. Thus, resistance exercise may be more feasible than aerobic exercise for MAFLD patients with poor fitness or for those who cannot tolerate or participate in aerobic exercise [210]. Overall, the selection of the type and duration of exercise must be based on patients' preference and the likelihood of long-term adherence. Notably, combined diet/exercise strategies are more effective in normalisation of liver enzymes levels, reducing hepatic steatosis and for improving histology than either modality alone [211].

What are practical recommendations for lifestyle intervention in MAFLD?

Recommendations

- Lifestyle change towards a healthy diet and physical activity norms via structured programmes are recommended for MAFLD (C2).
- Patients without steatohepatitis or fibrosis should receive counselling for a healthy diet and physical activity and no pharmacotherapy for their liver disease (B2).
- Both overweight/obese and nonobese MAFLD can benefit from weight loss. In the former, a 7–10% weight loss is the target of most lifestyle interventions and results in improvement of liver enzymes and histology (B1).
- Dietary recommendations should consider energy restriction and exclusion of MAFLD-mediating com-

ponents (processed food, food and beverages high in added fructose). A Mediterranean type diet is advisable (B1).

- Combined diet/exercise strategies are more effective in normalisation of liver enzymes levels and reducing liver fat and improving histology (B1).
- Both aerobic exercise and resistance training effectively reduce liver fat and should be tailored based on patient preferences to ensure long-term adherence. Resistance exercise may be more feasible than aerobic exercise for MAFLD patients with poor fitness (B2).

Bariatric and metabolic therapies (endoscopic approaches and surgery) for MAFLD

It is currently premature to consider foregut bariatric surgery as an established option to treat MAFLD [212]. Bariatric operations are traditionally offered to patients with MAFLD only if they qualify because of other obesity-related comorbidities [213]. While not an indication *per se*, MAFLD is present in 65–90% of all patients who undergo weight loss surgery [214, 215]. Under these circumstances, numerous retrospective and prospective observational cohort studies have investigated the potential utility of bariatric surgery on MAFLD parameters. According to recent systematic reviews and meta-analyses [216–218], resolution of hepatic steatosis was demonstrated in > 75% of patients. With respect to steatohepatitis, improvements in ballooning and lobular inflammation are consistently observed [216]. Remarkably, regression of fibrosis has been reported in 16 of the 18 studies that investigated postoperative fibrosis scores on liver biopsy [216]. A recent prospective study also suggested resolution of steatohepatitis and fibrosis in liver biopsies from 84% and 70.2% of patients 5 years later, respectively. Notably, the reduction in fibrosis commenced in the first year and continued over the 5-year follow-up [219]. However, the lack of randomized controlled trials comparing bariatric surgery (and the various surgical procedures) with other interventions prevents definitive assessment of the benefits and harms of this approach as a therapeutic option for MAFLD [214]. Patients with MAFLD-related cirrhosis merit special consideration as candidates for bariatric surgery because of their high perioperative risk with a reported operative mortality as high as 16.3% in patients with decompensated disease [220].

In light of the above evidence, bariatric surgery can be considered for MAFLD only if the following two criteria are met: (1) presence of other indications [e.g., $\text{BMI} > 35 \text{ kg/m}^2$ ($> 30 \text{ kg/m}^2$ in Asian people)] and (2) absence of liver cirrhosis or evidence of compensated cirrhosis without concomitant portal hypertension. The feasibility of weight

loss surgery for patients with MAFLD and $\text{BMI} \leq 35 \text{ kg/m}^2$ [$\leq 30 \text{ kg/m}^2$ in Asian people] is presently unclear and more results are needed to support this practice.

It is noteworthy that steatohepatitis and liver fibrosis have been reported as potential complications of jeunoileal bypass surgery [221]. Besides traditional bariatric operations, research in the field of MAFLD has begun to focus on the potential utility of endoscopic bariatric and metabolic therapies (EMBT) including intragastric balloons (IGBs) and endoscopic sleeve gastroplasty (ESG) [222]. EMBT are safer and less invasive than bariatric surgery, ultimately representing an attractive option for patients with MAFLD who qualify because of other obesity-related comorbidities. IGBs have been shown to improve MAFLD-related parameters in short-term studies, whereas ESG may potentially lead to resolution of MAFLD in the long term [222]. However, the purported benefits of EMBT in MAFLD warrant further evaluation in randomized controlled trials.

What are the recommendations for bariatric (metabolic) surgery in MAFLD?

Recommendations

- Bariatric (metabolic) surgery reduces liver fat and improves the histological lesions of MAFLD, including fibrosis (B1).
- Due to the high risk of post-operative complications from bariatric (metabolic) surgery in patients with cirrhosis, the decision should be individualised (C1).


Evidence for current drug therapies

Several anti-diabetic medications are reported to be beneficial for patients with MAFLD [212, 223]. Belfort et al. conducted a RCT of pioglitazone and demonstrated that 6-month treatment with pioglitazone improved hepatic steatosis, ballooning necrosis, and inflammation in steatohepatitis patients with prediabetes or T2DM [224]. Furthermore, 18-month treatment with pioglitazone significantly improved hepatic fibrosis in steatohepatitis patients with prediabetes or T2DM [225]. The beneficial effects of pioglitazone on hepatic histology has been reported in steatohepatitis patients with and without T2DM [226–229]. Weight gain, edema, the development of bladder cancer, and a decrease in bone mineral density are possible concerns with pioglitazone, and this therapy is not widely used [230, 231].

GLP-1a has been reported to improve hepatic histology including fibrosis in a RCT and meta-analyses [232–235]. GLP-1a also reduces body weight. However, GLP-1a causes gastrointestinal adverse effects including loss of appetite which can result in poor patient-reported outcomes [236]. SGLT2i has been reported to reduce hepatic fat content [237–239]. A pilot study on a small number of biopsy-proven steatohepatitis patients showed significant improvements in steatosis, ballooning, and fibrosis, which remained significant when compared with a historical placebo [240]. The effects of SGLT2i on hepatic fibrosis require further studies. Metformin does not improve hepatic histology in patients with MAFLD [241–244]. However, metformin improves IR [241, 243, 244] and reduces the risk of HCC in patients with MAFLD, though the studies have not been

Fig. 2 Monitoring protocol for patients with MAFLD in clinical practice

Monitoring protocol for patients with MAFLD in clinical practice



prospective or randomized [245, 246]. Importantly, both GLP-1a and SGLT2i have been shown to be beneficial in cardiovascular outcome in patients with T2DM.

Vitamin E has been reported to be effective in improving hepatic histology in patients with steatohepatitis [229, 247–249]. However, several studies have failed to demonstrate its beneficial effects and level 1 evidence is thus lacking [243, 250–252]. Recently, a propensity score matching analysis demonstrated that vitamin E decreases the risk of death or transplant and hepatic decompensation in patients with metabolic steatohepatitis with bridging fibrosis or cirrhosis [253]. The development of prostate cancer is a possible concern of vitamin E [254].

Statins did not show any beneficial effects on hepatic histology [255]. However, statins reduced cardiovascular morbidity in patients with MAFLD [255, 256]. Thus, statins should be considered in all patients with MAFLD with hyperlipidemia. However, the treatment of hyperlipidemia in patients with MAFLD appears suboptimal. In a multi-centre study, 58.9% of patients who were on a statin did not achieve their treatment target while 74.1% of patients who were not on statin should have been receiving therapy [257].

Pentoxifylline, a phosphodiesterase inhibitor with anti-inflammatory effects has been demonstrated in a meta-analysis to improve lobular inflammation and NAS without affecting lipid profiles. However, there was no significant improvement in other histological features, such as steatosis, ballooning or fibrosis [258].

Patients with MAFLD are at a high risk of hepatic fibrosis, HCC, cardiovascular events, and cancer. Thus, for any physician treating these patients, metabolic risk factor modification to improve long-term outcomes is an essential part of holistic management.

Monitoring progress and response to treatment

There is no accepted consensus on the optimal strategy for monitoring patients with MAFLD and their response to treatment [259]. Ideally, an optimal surveillance schedule should include routine biochemistry, assessment of comorbidities, and monitoring of hepatic fibrosis [260]. By taking into account that the severity of fibrosis is the main prognostic determinant in terms of both liver-related outcomes and mortality [261], those with advanced fibrosis merit the closest monitoring. Because patients with MAFLD are expected to progress at a mean of 0.12 (range: 0.07–0.18) fibrosis stage per year [262], the following schedule can be proposed as a general guidance (Fig. 2): (1) patients without fibrosis can be monitored at 2- or 3-year interval if there has been no worsening of concomitant metabolic risk factors; (2) patients with fibrosis should be monitored on an annual basis, and (3) patients with cirrhosis should undergo monitoring at 6-month intervals including surveillance for

HCC. In selected patients at high risk of liver disease progression, monitoring should include a repeat liver biopsy every 5 years, unless they have established cirrhosis [260]. Notably, a recent study showed that while the prevalence and incidence of MAFLD in patients with T2DM are high, few patients progress to advanced fibrosis in 3 years [136].

Although liver histology remains the primary endpoint in clinical trials, its routine use over time for serial surveillance of fibrosis progression is unfeasible owing to its known limitations (cost, invasiveness, risk of complications, subjective interpretation). However, no easily applicable method for use in daily practice with a high predictive value for differentiating different stages of liver fibrosis has been identified. Monitoring of fibrosis progression in the clinic might rely on a combination of noninvasive scores (NFS, FIB-4 and ADAPT) and LSM [263, 264] although this strategy requires further validation. Growing evidence supports the utility of magnetic resonance elastography for the non-invasive detection of fibrosis in early-phase trials of MAFLD [265]. However, this technique is expensive and cannot be recommended for routine clinical use.

How to monitor the progress of treatment in MAFLD?

Recommendations

- Patients without fibrosis can be monitored at intervals of 2 or 3 years in the absence of worsening of metabolic risk factors using a combination of non-invasive scores and liver stiffness measurement (C2).
- Patients with fibrosis should be monitored on an annual basis using a combination of non-invasive scores and liver stiffness measurement (C2).
- Patients with cirrhosis should undergo monitoring at 6-month intervals including surveillance for hepatocellular carcinoma (A2).
- In subgroup of patients at high risk of fibrosis progression, monitoring may include a repeated liver biopsy every 5 years' follow-up, unless they have established cirrhosis (C2).

Patient-reported outcomes in MAFLD

The multi-dimensional complexity of MAFLD management has highlighted the importance of understanding the disease from a patient perspective through Patient Reported Outcomes (PRO). This is particularly important as new drugs in development may have significant side effects, and economic and cost-effectiveness modelling are needed to identify the ideal target subpopulation for treatment.

Instruments assessing general health-related quality of life (HRQoL) questionnaires such as the Short Form-36 (SF-36), EuroQoL 5-Dimensions 5-Level (EQ-5D-5L), the Chronic Liver Disease Questionnaire (CLDQ) and more recently, disease-specific questionnaires such as CLDQ-NASH and NASH-CHECK have been validated in MAFLD [266–268]. These questionnaires have been translated into various languages and validated internationally. Other instruments looking more specifically at fatigue and work productivity have also been applied to MAFLD [266].

Patients with MAFLD appear to have worse HRQoL, physical, mental as well as fatigue scores compared to other causes of chronic liver disease such as chronic viral Hepatitis B and C [269–271]. Demographics or metabolic comorbidities that have been associated with these low HRQoL scores include age, female gender, depression, smoking, T2DM, and BMI, although MAFLD by itself is an independent risk factor [272, 273]. When referenced against the severity of liver disease, several studies using a variety of instruments have reported cirrhosis as an independent risk factor for lower HRQoL and physical health scores [269, 270, 272]. However, a European study which controlled for features of steatohepatitis found only lobular inflammation, but not histologic ballooning or cirrhosis, to be associated with poorer HRQoL scores [273]. Regardless, there is a dearth of MAFLD PRO data in the Asian context and how cultural variation may nuance the PROs is not known.

Patient perspectives on quality of life, satisfaction, and compliance with lifestyle advice are critical to developing and evolving to a patient-centred approach to impact MAFLD outcomes. This is all the more important because of the integral role of lifestyle in disease pathogenesis. Studies in Asian populations evaluating the improvement of PROs and the trade-off thresholds for side effects during therapy are needed to better guide and strategize approaches to this disease.

What is the role of patient reported outcomes in MAFLD?

Recommendations

- Patient perspectives on quality of life, satisfaction, and compliance are critical to developing a patient-centred approach to impact MAFLD outcomes (B2).

- Patients with MAFLD appear to have worse HRQoL, physical, mental, and fatigue scores compared to patients with other causes of chronic liver disease such as hepatitis B and C (B2).

The pipeline of new treatments

The past few years have witnessed a steady increase in the number of drug targets for MAFLD as new information about its molecular pathogenesis unfolds. At the end of 2019, it was estimated that there were 196 investigational candidate drugs for MAFLD in various stages of development [274]. The drugs that have so far progressed to phase 3 development include obeticholic acid (OCA), elafibranor, selonsertib, cenicriviroc, resmetirom, and aramchol [275]. Several challenges remain for having a drug approved for MAFLD treatment. This includes the tremendous heterogeneity of the disease, and as well, performance bias or the Hawthorne effect where the placebo group provided with lifestyle and regular medical advice in a clinical trial setting impacts on histological and biochemical responses.

OCA is a farnesoid X receptor agonist whose potential actions include decreasing hepatic steatosis, inflammation, and fibrosis and an increase of insulin sensitivity [276]. OCA is being tested at two different doses (10 mg/day and 25 mg/day) in the ongoing phase 3 Randomized Global Phase 3 Study to Evaluate the Impact on NASH with Fibrosis of Obeticholic Acid Treatment (REGENERATE) trial. This RCT is being conducted in ~ 2400 patients. The study has a dual primary endpoint consisting of resolution of steatohepatitis with no worsening of fibrosis and improvement of fibrosis by ≥ 1 stage with no worsening of steatohepatitis. An interim analysis of the RGENERATE trial has shown that treatment with OCA 25 mg/day resulted in an improvement of fibrosis without worsening of steatohepatitis in 21.0% ($p < 0.001$) of participants, whereas resolution of steatohepatitis without worsening of fibrosis was observed in 14.9% of patients ($p = 0.001$) [275, 277]. The main adverse event of OCA was pruritus which occurred in 51% of patients in the 25-mg group, 28% in the 10-mg group, and 19% in the placebo group. Notably, 9% of patients in the 25-mg group discontinued the drug because of pruritus. Over the 18-month trial duration, cholelithiasis or cholecystitis was observed in 3% ($n = 19$) of patients in the 25-mg group, 1% ($n = 7$) in the 10-mg group, and < 1% ($n = 2$) in the placebo group [277]. A caveat to the use of OCA is increases in serum low-density lipidprotein (LDL) and decreases in high-density lipidprotein (HDL), which may be partially countered by statin therapy [275, 278]. Although cirrhosis was an exclusion criterion for the RGENERATE trial [279], an ongoing

study (NCT03439254) is focusing on the dosing of OCA in patients with steatohepatitis and concomitant compensated cirrhosis. Recently, the FDA determined that the predicted benefit of OCA remains uncertain and did not warrant accelerated approval under subpart H.

Elafibranor, a dual peroxisome proliferator-activated receptor alpha/delta agonist (PPAR α/δ) agonist was found to induce resolution of steatohepatitis without worsening of fibrosis in the GOLDEN Study 2b Trial [280]. The same endpoint is used as the primary outcome measure in the ongoing phase 3 clinical trial of elafibranor (RESOLVE-IT). Unfortunately, the study did not meet the predefined surrogate primary endpoint of steatohepatitis resolution without worsening of fibrosis, though the trial is ongoing. The study will also provide data on long-term outcomes including all-cause mortality, cirrhosis, and liver-related clinical endpoints.

Selonsertib, an inhibitor of apoptosis signal-regulating kinase-1 (ASK-1) showed promise in improving hepatic inflammation and fibrosis in animal models and advanced to phase 3 (STELLAR-3 and -4) but was discontinued because it was not superior to placebo in both trials [281]. Cenicriviroc, a CCR2/CCR5 chemokine receptor blocker aims to reduce the drivers of inflammation and fibrosis [282]. A multicentre, randomised, double-blind, placebo-controlled study of cenicriviroc for the treatment of fibrosis in MAFLD (AURORA) is currently underway. The primary outcome is improvement of fibrosis without worsening of steatohepatitis. Resmetirom is a liver-directed, orally active, selective thyroid hormone receptor- β agonist designed to improve steatohepatitis by increasing hepatic fat metabolism and reducing lipotoxicity [283]. A phase 3 study in patients with advanced liver fibrosis, MAESTRO-NASH is ongoing with the primary endpoint being resolution of steatohepatitis after 1 year. Aramchol, a cholic-arachidic acid conjugate that inhibits stearoyl-CoA desaturase was initially produced for treatment of gallstones [284]. Aramchol 600 mg is currently being tested in a phase 3/4 study (ARMOR) to assess its efficacy and safety in subjects with steatohepatitis and fibrosis stages 2–3 who are overweight or obese and have prediabetes or T2DM. In addition to these phase 3 clinical trials, a number of early phase trials are underway. While target-based therapeutic agents are being developed based on new pathophysiological knowledge and the drug discovery pipeline in MAFLD has been promising, the results have been below expectations. A combination drug treatment strategy wherein several drivers of disease are simultaneously engaged could be more effective than targeting individual drivers, since redundancy is common in biological systems.

Future clinical trials should consider the mechanism of action of the drug, and as well better stratification of patients and standardization of lifestyle interventions, exercise, and diet between treatment arms. Further trials should consider innovative designs such as basket, adaptive or umbrella trials [28].

Special groups

Lean subjects with MAFLD often have visceral obesity, sarcopenia, and recent weight gain. They also have a higher prevalence of features of the metabolic syndrome compared to lean controls and can develop steatohepatitis and advanced fibrosis [285, 286]. A recent RCT from Hong Kong suggested that lifestyle intervention is effective in treating MAFLD even in non-obese patients. The amount of weight reduction needed to achieve remission was less than that for non-obese patients. By 6 years, non-obese patients remained more likely to maintain weight reduction and have ALT normalization [287]. Similar findings were observed in a study from Turkey where 5% body weight loss induced MAFLD remission in both obese and lean patients with MAFLD [288]. Similarly, a small biopsy-based study revealed that 5% weight reduction is associated with improvement of steatohepatitis in non-obese patients, similar to that which is observed in obese patients [289]. Larger biopsy-based studies are required to confirm the findings. Non-obese subjects are more likely than obese subjects to maintain weight reduction and normal liver enzymes in the long term [287]. Therefore, lifestyle intervention with regular exercise is effective in treating MAFLD and in improving overall fitness and metabolic co-morbidities irrespective of baseline BMI. A 3–5% weight reduction may be sufficient in lean MAFLD.

Pediatric MAFLD is the most common cause of liver disease in children and may represent a more severe phenotype that will benefit from early intervention. The management of MAFLD in children consists of treating the liver disease itself, but more importantly addressing the underlying obesity and the related comorbidities. The overall goal is to improve a child's quality of life and reduce long-term metabolic, cardiovascular, and liver complications. Lifestyle changes (dietary interventions, physical activity, and nutritional and psychologic counselling) lead to significant improvements in BMI, aminotransferase levels, and hepatic steatosis in children with MAFLD [290]. While the efficacy of several medications including metformin, vitamin E, omega-3 fatty acid supplementation and probiotics has been investigated in children, intensive lifestyle modification remains the only prevention and treatment strategy for pediatric MAFLD at this stage.

What is the approach for management of special groups (non-obese and pediatric) with MAFLD?

Recommendations

- Lifestyle intervention with regular exercise is effective in treating MAFLD and in improving overall fitness and metabolic co-morbidities irrespective of baseline BMI (B1).
- Lifestyle change (dietary interventions, physical activity, and nutritional and psychologic counselling) is the only prevention and treatment strategy for pediatric MAFLD, though beneficial effects on fibrosis are yet to be demonstrated. No effective and safe drug treatment for fibrosis in pediatric MAFLD has been proven (B1).

Management of MAFLD-related HCC

The survival rate of patients with MAFLD-related HCC is similar to that from other etiologies [94, 291–294]. While a high prevalence of non-cirrhosis is a feature of MAFLD-related HCC, patients with non-cirrhotic MAFLD-related HCC have a similar risk of mortality as cirrhotic patients with disease from other etiologies [94, 293–295]. Accordingly, metabolic risk factor modification significantly contributes to their optimum management.

High BMI is one of three criteria for MAFLD diagnosis and its negative impact on HCC-related mortality has been reported in western cohorts [296]. However, there is no association between high BMI and HCC-related mortality in Asian patients in a meta-analysis or in cohort studies [296–298]. The reason(s) for this discrepancy remain(s) unclear but sarcopenia could be a possible explanation. Sarcopenia is a prognostic factor for Asian patients with HCC [297, 299–305], while physical activity is reported to be associated with better survival in patients with HCC [306]. Thus, an important aspect of management is by considering body composition that includes body fat and skeletal muscle mass, when treating patients with HCC.

T2DM is another criteria for MAFLD in the context of hepatic steatosis. In this regard, an international cohort study demonstrated that metformin significantly reduced the risk of HCC in MAFLD patients with HbA1c levels above 7.0% [245]. A meta-analysis has also shown that metformin prolongs the survival of HCC patients with T2DM after the curative treatment of the cancer [246]. Thus, metformin may be a beneficial treatment along with life-style intervention, in MAFLD-related HCC patients with T2DM. Again, however, there are no prospective, randomized data to support this contention and thus no strong recommendation can be made.

The Japan Study Group for MAFLD has performed a nationwide study and created a data mining-based prognostic algorithm for patients with MAFLD-related HCC [307]. The decision-tree revealed that the best profile comprised treatment with hepatectomy or radiofrequency ablation and a serum albumin level ≥ 3.7 g/dL [307]. However, these need confirmation in other international cohorts.

What is the approach to management of MAFLD-HCC?

Recommendations

- Control of diabetes and obesity could be beneficial in MAFLD-related HCC patients (B1).
- Metformin may be a beneficial treatment in MAFLD-related HCC patients with T2DM (C2).
- Serum albumin level is a prognostic factor and nutritional therapy focusing on protein metabolism is important for the management of patients with MAFLD-related HCC (C2).

Liver transplantation for MAFLD

MAFLD has become an increasingly frequent indication for liver transplantation (LT) in the Asia-Pacific region over the past decade, both as a sole etiologies or co-existing with other conditions [308–310]. With increasingly effective vaccination programs and anti-viral medication, it is likely that MAFLD will continue to increase as a LT indication. MAFLD transplant recipients are typically older, with a higher BMI and are more likely to have T2DM and hypertension than non-MAFLD recipients [311, 312]. Not surprisingly, MAFLD patients have a higher likelihood of underlying cardiovascular disease (CVD) which was up to 53% in one North American series of patients undergoing pre-LT coronary angiography [313]. Thus a careful CVD evaluation is mandatory as pre-existing CVD along with age predicts post-LT cardiovascular events [314].

MAFLD patients have a 60% higher risk of developing a major adverse cardiovascular event (MACE) within 30 days post-LT, and this predicts a lower post-LT survival [315]. Consequently, the United Network for Organ Sharing data suggests CVD-specific mortality is increased in transplanted MAFLD patients relative to other etiologies, and relates to pre-existing risk factors for T2DM, renal impairment, and prior CVD [316]. MAFLD may also be associated with a pro-coagulant state with reports of an increased risk of portal vein thrombosis complicating transplantation [317, 318].

Importantly, post-LT survival in MAFLD patients is equivalent to that from other etiologies, with 5-year overall survival rates of 73–79% [311, 319]. Infection (22–25%), and CVD (5–22%) were identified as the commonest causes of post-LT death [311, 320]. Older age (> 60 years), female gender, higher MELD (> 23), and extremes of BMI (< 18.5 and > 40 kg/m²) were reported to predict post-LT death in the European Liver Transplant Registry [311].

Recurrence of MAFLD in the graft is common, occurring in up to 90% of recipients [321]. A minority of patients have an accelerated disease course with graft cirrhosis developing in 2–4% of patients in less than a decade; however, death from graft cirrhosis is uncommon (0.2–3% of patients) [320, 321]. Corticosteroids and calcineurin antagonists are well-established immunosuppressive regime in LT with known risks to exacerbate hyperglycemia, hypertension, and dyslipidemia; hence the optimal regime in MAFLD recipients is unclear. Statins should be encouraged post-LT in those with dyslipidemia and/or pre-existing CVD and may be associated with a survival benefit [322].

What are the recommendations for liver transplantation in MAFLD?

Recommendations

- Post-transplant survival for MAFLD patients is equivalent to that of other liver diseases in appropriately selected patients. Liver transplantation should be considered for MAFLD patients with decompensated liver disease or hepatocellular carcinoma (B1).
- Patients with MAFLD cirrhosis have a high prevalence of pre-existing cardiovascular disease and should be thoroughly evaluated prior to listing for transplantation (B1).

Conclusion

The APASL guidelines document for MAFLD (along with the criteria for diagnosis) is intended to provide assessment and management advice for the general as well as special populations with the disease. The burden of MAFLD is rapidly increasing in the Asia-Pacific; in this region dual etiology disease particularly with viral hepatitis and alcohol is common. MAFLD is a leading cause of chronic liver disease and increasingly of HCC on the one hand and is a contributor to the various associated systemic complications such as T2DM, CVD, and CKD. Fibrosis is the major determinant of all the complications of MAFLD and liver biopsy remains the reference standard. However, various biomarkers and imaging modalities are available (and are being increasingly

used) for the non-invasive assessment of fibrosis. Patients with cirrhosis should be considered for surveillance for varices and HCC. Lifestyle intervention remains the cornerstone of management but it is expected that over the next decade, drug treatments will be approved and added to the armamentarium of therapeutic choices. Holistic patient-centred and multidisciplinary management approaches are required that focus on the amelioration of liver injury, treating the associated systemic metabolic dysfunction, while being aware of the importance of patient-reported outcomes.

Funding None.

Compliance with ethical standards

Conflict of interest Mohammed Eslam, Shiv K. Sarin, Vincent Wai-Sun Wong, Jian-Gao Fan, Takumi Kawaguchi, Sang Hoon Ahn, Ming-Hua Zheng, Gamal Shiha, Yusuf Yilmaz, Rino Gani, Shahinul Alam, Dan Yock Young, Jia-Horng Kao, Saeed Hamid, Ian Homer Cua, Wah-Kheong Chan, Diana Payawal, Soek-Siam Tan, Tawesak Tanwandee, Leon A. Adams, Manoj Kumar, Masao Omata, Jacob George disclose no conflicts.

References

1. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, Jia J, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology and hepatology Commission. Lancet Gastroenterol Hepatol 2020;5:167–228.
2. Wong MC, Huang JL, George J, Huang J, Leung C, Eslam M, Chan HL, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol 2019;16:57–73.
3. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ 2001;323:334–336.
4. Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2019;4:389–398.
5. Hu X, Huang Y, Bao Z, Wang Y, Shi D, Liu F, Gao Z, et al. Prevalence and factors associated with nonalcoholic fatty liver disease in Shanghai work-units. BMC Gastroenterol 2012;12:123.
6. Fan J-G, Zhu J, Li X-J, Chen L, Li L, Dai F, Li F, et al. Prevalence of and risk factors for fatty liver in a general population of Shanghai. China J Hepatol 2005;43:508–514.
7. Li H, Guo M, An Z, Meng J, Jiang J, Song J, Wu W. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int J Environ Res Public Health 2020;17:1818.
8. Zhou Y-J, Li Y-Y, Nie Y-Q, Ma J-X, Lu L-G, Shi S-L, Chen M-H, et al. Prevalence of fatty liver disease and its risk factors in the population of South China. World J Gastroenterol 2007;13:6419.
9. Li H, Wang Y-J, Tan K, Zeng L, Liu L, Liu F-J, Zhou T-Y, et al. Prevalence and risk factors of fatty liver disease in Chengdu. Southwest China Hepatobiliary Pancreat Dis Int 2009;8:377–382.
10. Chen CH, Huang MH, Yang JC, Nien CK, Yang CC, Yeh YH, Yueh SK. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance

of nonalcoholic fatty liver disease in nonobese adults. *J Clin Gastroenterol* 2006;40:745–752.

11. Hung SC, Lai SW, Chen MC, Li PC, Lin KC. Prevalence and related factors of non-alcoholic fatty liver disease among the elderly in Taiwan. *Eur Geriatr Med* 2013;4:78–81.
12. Tung TH, Chang TH, Chiu WH, Lin TH, Shih HC, Chang MH, Liu JH. Clinical correlation of nonalcoholic fatty liver disease in a Chinese taxi drivers population in Taiwan: Experience at a teaching hospital. *BMC Res Notes* 2011;4:315.
13. Wei JL, Leung JC, Loong TC, Wong GL, Yeung DK, Chan RS, Chan HL, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. *Am J Gastroenterol* 2015;110:1306–1314.
14. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. *Ann Intern Med* 2005;143:722–728.
15. Jeong EH, Jun DW, Cho YK, Choe YG, Ryu S, Lee SM, Jang EC. Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do. *Korea Clin Mol Hepatol* 2013;19:266–272.
16. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. *J Gastroenterol* 2003;38:954–961.
17. Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, Dhibar T, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. *Hepatology* 2010;51:1593–1602.
18. Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, et al. Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. *Trop Gastroenterol* 2004;25:76–79.
19. Amarapurkar D, Kamani P, Patel N, Gupte P, Kumar P, Agal S, Bajjal R, et al. Prevalence of non-alcoholic fatty liver disease: population based study. *Ann Hepatol*. 2007;6:161–163.
20. Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, Ahsan M, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. *JGH Open* 2018;2:39–46.
21. Dassanayake AS, Kasturiratne A, Rajindrajith S, Kalubowila U, Chakravarthi S, De Silva AP, Makaya M, et al. Prevalence and risk factors for non-alcoholic fatty liver disease among adults in an urban Sri Lankan population. *J Gastroenterol Hepatol* 2009;24:1284–1288.
22. Mohan V, Farooq S, Deepa M, Ravikumar R, Pitchumoni CS. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome. *Diabetes Res Clin Pract* 2009;84:84–91.
23. Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. *Hepatol Int* 2013;7:548–554.
24. Chow WC, Tai ES, Lian SC, Tan CK, Sng I, Ng HS. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore. *Singapore Med J* 2007;48:752–757.
25. Chan WK, Tan ATB, Vethakkan SR, Tah PC, Vijayananthan A, Goh KL. Non-alcoholic fatty liver disease in diabetics—prevalence and predictive factors in a multiracial hospital clinic population in Malaysia. *J Gastroenterol Hepatol* 2013;28:1375–1383.
26. Chan W-K, Bahar N, Razlan H, Vijayananthan A, Sithaneshwar P, Goh K-L. Non-alcoholic fatty liver disease in a young multi-racial Asian population: a worrying ethnic predilection in Malay and Indian males. *Hepatol Int* 2014;8:121–127.
27. Wong VW-S, Wong GL-H, Yeung DK-W, Lau TK-T, Chan CK-M, Chim AM-L, Abrigo JM, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. *J Hepatol* 2015;62:182–189.
28. Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. *Gastroenterology* 2019;157:590–593.
29. Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, Wong VW, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. *J Hepatol* 2020. <https://doi.org/10.1016/j.jhep.2020.03.039>.
30. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. *Liver Int* 2020. <https://doi.org/10.1111/liv.14548>.
31. DHHS D. 2020 Dietary Guidelines for Americans. 2015. <https://health.gov/dietaryguidelines/2015/guidelines>. Accessed 10 June 2020.
32. Choi HS, Brouwer WP, Zanfir WM, de Man RA, Feld JJ, Hansen BE, Janssen HL, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. *Hepatology* 2020;71:539–548.
33. Chiang DJ, McCullough AJ. The impact of obesity and metabolic syndrome on alcoholic liver disease. *Clin Liver Dis* 2014;18:157.
34. Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SR, Tymeson HD, Venkateswaran V, et al. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018;392:1015–1035.
35. Chang Y, Cho YK, Kim Y, Sung E, Ahn J, Jung HS, Yun KE, et al. Nonheavy DRINKING and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. *Hepatology* 2019;69:64–75.
36. Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, et al. Among patients with nonalcoholic fatty liver disease, modest alcohol use is associated with less improvement in histologic steatosis and steatohepatitis. *Clin Gastroenterol Hepatol* 2018;16(1511–1520):e1515.
37. Ekstedt M, Franzén LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, Ekstedt M, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. *Scand J Gastroenterol* 2009;44:366–374.
38. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. *J Clin Gastroenterol* 2004;38:705–709.
39. Khattab M, Eslam M, Sharwae MA, Shatat M, Ali A, Hamdy L. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. *Am J Gastroenterol* 2010;105:1970–1977.
40. Khattab MA, Eslam M, Mousa YI, Ela-adawy N, Fathy S, Shatat M, Abd-Aalhalim H, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. *Ann Hepatol* 2012;11:487–494.
41. Eslam M, Ampuero J, Jover M, Abd-Elhalim H, Rincon D, Shatat M, Camacho I, et al. Predicting portal hypertension and variceal bleeding using non-invasive measurements of metabolic variables. *Ann Hepatol* 2013;12:420–430.
42. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. *Hepatology* 2003;38:75–85.
43. Adinolfi LE, Restivo L, Zampino R, Guerrera B, Lonardo A, Ruggiero L, Riello F, et al. Chronic HCV infection is a risk of atherosclerosis. Role of HCV and HCV-related steatosis. *Atherosclerosis* 2012;221:496–502.
44. Eslam M, Booth DR, George J, Ahlenstiel G. Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism

in chronic hepatitis C virus infection. *World J Gastroenterol* 2013;19:7055.

45. Tada T, Kumada T, Toyoda H, Sone Y, Takeshima K, Ogawa S, Goto T, et al. Viral eradication reduces both liver stiffness and steatosis in patients with chronic hepatitis C virus infection who received direct-acting anti-viral therapy. *Aliment Pharmacol Ther* 2018;47:1012–1022.
46. Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. *Gut* 2011;60:1139–1151.
47. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. *Hepatology* 2017;65:828–835.
48. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. *J Gastroenterol Hepatol* 2011;26:1361–1367.
49. Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, Tanwandeer T. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. *Liver Int* 2017;37:542–551.
50. Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, Chan HL, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2017;32:667–676.
51. Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. *World J Gastroenterol* 2018;24:1269.
52. Peleg N, Issachar A, Arbib OS, Cohen-Naftaly M, Braun M, Leshno M, Barsheshet A, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. *JHEP Rep* 2019;1:9–16.
53. Chandalia M, Lin P, Seenivasan T, Livingston EH, Snell PG, Grundy SM, Abate N. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. *PLoS One* 2007;2:e812.
54. Petersen KF, Dufour S, Feng J, Befroy D, Dziura J, Dalla Man C, Cobelli C, et al. Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men. *Proc Natl Acad Sci USA* 2006;103:18273–1827.
55. Gujral UP, Pradeepa R, Weber MB, Narayan KM, Mohan V. Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations. *Ann N Y Acad Sci* 2013;1281:51–63.
56. Kuk JL, Church TS, Blair SN, Ross R. Measurement site and the association between visceral and abdominal subcutaneous adipose tissue with metabolic risk in women. *Obesity* 2010;18:1336–1400.
57. Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, Couch W, et al. Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. *Am J Clin Nutr* 2008;88:1263–1271.
58. Lim U, Ernst T, Buchthal SD, Latch M, Albright CL, Wilkens LR, Kolonel LN, et al. Asian women have greater abdominal and visceral adiposity than Caucasian women with similar body mass index. *Nutr Diabetes* 2011. <https://doi.org/10.1038/nutd.2011.2>.
59. Araneta MR, Barrett-Connor E. Ethnic differences in visceral adipose tissue and type 2 diabetes: Filipino, African-American, and white women. *Obes Res* 2005;13:1458–1465.
60. Lear SA, Humphries KH, Kohli S, Birmingham CL. The use of BMI and waist circumference as surrogates of body fat differs by ethnicity. *Obesity* 2007;15:2817–2824.
61. Park YW, Allison DB, Heymsfield SB, Gallagher D. Larger amounts of visceral adipose tissue in Asian Americans. *Obes Res* 2001;9:381–387.
62. Consultation WHOE. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157–163.
63. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. *Lancet* 2011;377:557–567.
64. Doycheva I, Patel N, Peterson M, Lomba R. Prognostic implication of liver histology in patients with nonalcoholic fatty liver disease in diabetes. *J Diabetes Compl* 2013;27:293–300.
65. Fracanzani AL, Petta S, Lombardi R, Pisano G, Russello M, Consonni D, Di Marco V, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity. *Clin Gastroenterol Hepatol* 2017;15:1604.
66. Eslam M, Fan J-G, Mendez-Sanchez N. Non-alcoholic fatty liver disease in non-obese individuals: the impact of metabolic health. *Lancet Gastroenterol Hepatol* 2020;5:71.
67. Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, Yang H, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol* 2020. [https://doi.org/10.1016/S2468-1253\(20\)30077-7](https://doi.org/10.1016/S2468-1253(20)30077-7).
68. Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a meta-analysis. *Medicine* 2017;96:8179.
69. Ampuero J, Aller R, Gallego-Duran R, Banales JM, Crespo J, Garcia-Monzon C, Pareja MJ, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. *Aliment Pharmacol Ther* 2018;48:1260–1270.
70. Zou T-T, Zhang C, Zhou Y-F, Han Y-J, Xiong J-J, Wu X-X, Chen Y-P, et al. Lifestyle interventions for patients with non-alcoholic fatty liver disease: a network meta-analysis. *Eur J Gastroenterol Hepatol* 2018;30:747–755.
71. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. *Nat Rev Gastroenterol Hepatol* 2016;13:412–425.
72. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, Magris M, et al. Human gut microbiome viewed across age and geography. *Nature* 2012;486:222–2227.
73. Lin A, Bik EM, Costello EK, Dethlefsen L, Haque R, Relman DA, Singh U. Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. *PLoS One* 2013;8:53838.
74. Mah KW, Sangsupawanich P, Tunyapanit W, van Bever H, Shek LP, Chua KY, Lee BW. Gut microbiota of children living in rural south Thailand and urban Singapore. *Allergol Int* 2008;57:65–71.
75. Chong CW, Ahmad AF, Lim YAL, Teh CSJ, Yap IKS, Lee SC, Chin YT, et al. Effect of ethnicity and socioeconomic variation to the gut microbiota composition among pre-adolescent in Malaysia. *Sci Rep* 2015. <https://doi.org/10.1038/srep13338>.
76. Bayoumi A, Grønbæk H, George J, Eslam M. The epigenetic drug discovery landscape for metabolic-associated fatty liver disease. *Trends Genet* 2020. <https://doi.org/10.1016/j.tig.2020.03.003>.
77. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: clinical impact. *J Hepatol* 2018;68:268–279.
78. Eslam M, George J. Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology. *Nat Rev Gastroenterol Hepatol* 2019;17:40–52.
79. Pacifico L, Perla FM, Chiesa C. Sarcopenia and nonalcoholic fatty liver disease: a causal relationship. *Hepatobiliary Surg Nutr* 2019;8:144.

80. Mohanty SR, Troy TN, Huo D, O'Brien BL, Jensen DM, Hart J. Influence of ethnicity on histological differences in non-alcoholic fatty liver disease. *J Hepatol*. 2009;50:797–804.

81. Schneider AL, Lazo M, Selvin E, Clark JM. Racial differences in nonalcoholic fatty liver disease in the US population. *Obesity (Silver Spring)* 2014;22:292–299.

82. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. *Hepatology* 2004;40:1387–1395.

83. Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? *J Gastroenterol Hepatol* 2011;26:501–509.

84. Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR. Ethnicity and the diagnosis gap in liver disease: a population-based study. *Br J Gen Pract* 2014;64:e694–702.

85. Wong VWS, Chu WCW, Wong GLH, Chan RSM, Chim AML, Ong A, Yeung DKW, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. *Gut* 2012;61:409–415.

86. Pollicino T, Saitta C. Occult hepatitis B virus and hepatocellular carcinoma. *World J Gastroenterol* 2014;20:5951–5961.

87. Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? *Hepatol Res* 2012;42:1–14.

88. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, Kobayashi M, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. *Am J Gastroenterol* 2012;107:253–261.

89. Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, Kim YJ, Yoon JH, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. *Digestion* 2011;84(Suppl 1):17–22.

90. Vongsuvanh R, van der Poorten D, George J. Non-alcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. *Hepatol Int* 2013;7(Suppl 2):823–832.

91. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, et al. Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030. *J Hepatol* 2018;69:896–904.

92. Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, Hu TH, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. *Aliment Pharmacol Ther* 2020;51:801–811.

93. Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. *Hepatology* 2010;51:1972–1978.

94. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, Bellentani S, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. *Hepatology* 2016;63:827–838.

95. Bhala N, Angulo P, van der Poorten D, Lee E, Hui JM, Saracco G, Adams LA, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. *Hepatology* 2011;54:1208–1216.

96. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. *Hepatology* 2002;36:1349–1354.

97. Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, Tamagawa Y, et al. Cryptogenic cirrhosis in the region where obesity is not prevalent. *World J Gastroenterol* 2006;12:2080–2085.

98. Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. *Hum Pathol* 2010;41:425–430.

99. Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J, Zheng MH. From NAFLD to MAFLD: a ‘redefining’ moment for fatty liver disease. *Chin Med J (Engl)* 2020. <https://doi.org/10.1097/CM1099.00000000000000989>.

100. Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, et al. Nonalcoholic fatty liver disease contributes to sub-clinical atherosclerosis: a systematic review and meta-analysis. *Hepatol Commun* 2018;2:376–392.

101. Sinn DH, Cho SJ, Gu S, Seong D, Kang D, Kim H, Yi BK, et al. Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis. *Gastroenterology* 2016;151(481–488):e481.

102. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. *J Hepatol* 2016;65:589–600.

103. Zhou Y-Y, Zhou X-D, Wu S-J, Hu X-Q, Tang B, Sv P, Pan X-Y, et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a meta-analysis. *Eur J Gastroenterol Hepatol* 2018;30:631–636.

104. Keskin M, Hayiroglu MI, Uzun AO, Guvenc TS, Sahin S, Kozan O. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. *Am J Cardiol* 2017;120:1720–1726.

105. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015;149(389–397):e310.

106. Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. *J Hepatol* 2016;65:425–443.

107. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. *PLoS Med* 2014;11:e1001680.

108. Khoo S, Wong VW, Goh GB, Fan J, Chan WK, Seto WK, Chow WC. Suboptimal treatment of dyslipidemia in patients with non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2019. <https://doi.org/10.1111/jgh.14794>.

109. Athyros VG, Alexandrides TK, Bilianou H, Cholongitas E, Doumas M, Ganotakis ES, Goudevenos J, et al. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. *Metabol* 2017;71:17–32.

110. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 diabetes management algorithm 2018 executive summary. *Endocr Pract* 2018;24:91–120.

111. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med* 2015;373:2117–2288.

112. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med* 2016;375:311–322.

113. Wong VW, Adams LA, de Ledinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. *Nat Rev Gastroenterol Hepatol* 2018;15:461–478.

114. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Gual- lar E, Clark JM. Diagnostic accuracy and reliability of ultrasoundography for the detection of fatty liver: a meta-analysis. *Hepatology* 2011;54:1082–1090.

115. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. *J Hepatol* 2017;66:1022–1030.

116. Wong VW, Petta S, Hiriart JB, Camma C, Wong GL, Marra F, Vergniol J, et al. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. *J Hepatol* 2017;67:577–584.

117. Caussy C, Alquiraish MH, Nguyen P, Hernandez C, Cepin S, Fortney LE, Ajmera V, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. *Hepatology* 2018;67:1348–1359.

118. Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. *Hepatology* 2018;68:763–772.

119. Bril F, Barb D, Lomonaco R, Lai J, Cusi K. Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. *J Hepatol* 2020;72:401–410.

120. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. *BMC Gastroenterol* 2006;6:33.

121. Ballestri S, Lonardo A, Romagnoli D, Carulli L, Losi L, Day CP, Loria P. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. *Liver Int* 2012;32:1242–1252.

122. Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Gastroenterology* 2020;158(1611–1625):e1612.

123. Rios RS, Zheng KI, Targher G, Byrne CD, Zheng MH. Noninvasive fibrosis assessment in NAFLD. *Chin Med J (Engl)* 2020. <https://doi.org/10.1097/CM.0000000000000989>.

124. Wai C-T, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology* 2003;38:518–526.

125. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski SM, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology* 2006;43:1317–1325.

126. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* 2007;45:846–854.

127. Kaya E, Bakir A, Eren F, Yilmaz Y. The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases. *Hepatol Forum* 2020. <https://doi.org/10.14744/hf.2020.0006>.

128. Alkayyali T, Qutranji L, Kaya E, Bakir A, Yilmaz Y. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease. *Acta Diabetol* 2020. <https://doi.org/10.1007/s00592-019-01467-7>.

129. Mahady SE, Macaskill P, Craig JC, Wong GLH, Chu WCW, Chan HLY, George J, et al. Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis. *Clin Gastroenterol Hepatol* 2017;15(1453–1460):e1451.

130. Hagstrom H, Talback M, Andreasson A, Walldius G, Hammar N. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. *Gastroenterology* 2020;158:200–214.

131. Mofrad P, Contos MJ, Haque M, Sergeant C, Fisher RA, Luketic VA, Sterling RK, et al. Clinical and histologic spectrum of non-alcoholic fatty liver disease associated with normal ALT values. *Hepatology* 2003;37:1286–1292.

132. Gao F, Huang JF, Zheng KI, Pan XY, Ma HL, Liu WY, Byrne CD, et al. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. *J Gastroenterol Hepatol* 2020. <https://doi.org/10.1111/jgh.15055>.

133. Zheng KI, Liu WY, Pan XY, Ma HL, Zhu PW, Wu XX, Targher G, et al. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. *BMJ Open Diabetes Res Care* 2020. <https://doi.org/10.1136/bmjdrc-2020-001174>.

134. Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. *Hepatology* 2019;70:1521–1530.

135. Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, et al. ADAPT: An Algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. *Hepatology* 2019;69:1075–1086.

136. Lee HW, Wong GL, Kwok R, Choi KC, Chan CK, Shu SS, Leung JK, et al. Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study. *Hepatology* 2020. <https://doi.org/10.1002/hep.31142>.

137. Shih GE, El-Etreby S, Bahgat M, Hamed M, El Sherbini M, Ghoneem EA, Zalata K, et al. Chronic hepatitis C patients with obesity: do we need two operators for accurate evaluation of liver stiffness? *Ann Hepatol* 2018;17:795–801.

138. Wong VW, Irles M, Wong GL, Shih S, Chan AW, Merrouche W, Shu SS, et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. *Gut* 2019;68:2057–2064.

139. Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. *Hepatology* 2017;66:1486–1501.

140. Fu C, Wai JW, Nik Mustapha NR, Irles M, Wong GL, Mahadeva S, Shih S, et al. Performance of simple fibrosis scores in non-obese patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2019. <https://doi.org/10.1016/j.cgh.2019.09.027>.

141. Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, et al. Optimizing use of non-alcoholic fatty liver disease fibrosis Score, fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis. *Clin Gastroenterol Hepatol* 2019;17(2570–2580):e2537.

142. Imao K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H, Fujita K, et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. *Gastroenterology* 2016;150:626.

143. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with

Biopsy-Proven nonalcoholic fatty liver disease. *Gastroenterology* 2017;152(598–607):e592.

144. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease—the role of transient elastography and plasma cytokeratin-18 fragments. *Aliment Pharmacol Ther* 2014;39:254–269.

145. Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK, Yilmaz Y, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol* 2020;5:362–373.

146. Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, et al. Liver ultrasound elastography: an update to the world federation for ultrasound in medicine and biology guidelines and recommendations. *Ultrasound Med Biol* 2018;44:2419–2440.

147. Loria P, Lonardo A, Lombardini S, Carulli L, Verrone A, Ganazzi D, Rudolfo A, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. *J Gastroenterol Hepatol* 2005;20:1176–1184.

148. Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. *Surg Obes Relat Dis* 2019;15:502–511.

149. Wong VW, Chitturi S, Wong GL, Yu J, Chan HL, Farrell GC. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. *Lancet Gastroenterol Hepatol* 2016;1:56–67.

150. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. *Mayo Clin Proc* 1980;55:434–438.

151. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. *Am J Gastroenterol* 1999;94:2467–2474.

152. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005;41:1313–1321.

153. Bedossa P, Poitou C, Veyrie N, Bouillot JL, Basdevant A, Paradis V, Tordjman J, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. *Hepatology* 2012;56:1751–1759.

154. Bedossa P, Consortium FP. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. *Hepatology* 2014;60:565–575.

155. Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. *J Hepatol* 2020;72:828–838.

156. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol* 2020. <https://doi.org/10.1016/j.jhep.2020.03.039>.

157. Wong VW, Vergniol J, Wong GL, Foucher J, Chan HL, Le Bail B, Choi PC, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. *Hepatology* 2010;51:454–462.

158. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastian G, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. *Hepatology* 2017;65:1557–1655.

159. de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015;63:743–752.

160. Boursier J, Vergniol J, Guillet A, Hiriart JB, Lannes A, Le Bail B, Michalak S, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. *J Hepatol* 2016;65:570–578.

161. Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwithaya P, Duseja A, et al. Optimizing use of nonalcoholic fatty liver disease fibrosis score, fibrosis-4 Score, and liver stiffness measurement to identify patients with advanced fibrosis. *Clin Gastroenterol Hepatol* 2019. <https://doi.org/10.1016/j.cgh.2019.03.006>.

162. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. *J Hepatol* 2006;44:217–231.

163. Scaglione S, Kliethermes S, Cao G, Shoham D, Durazo R, Luke A, Volk ML. The epidemiology of cirrhosis in the United States: a population-based study. *J Clin Gastroenterol* 2015;49:690–696.

164. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Ünalp A, Network NCR. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. *J Hepatol* 2008;48:829–834.

165. Berzigotti A, Merkel C, Magalotti D, Tiani C, Gaiani S, Sacerdoti D, Zoli M. New abdominal collaterals at ultrasound: a clue of progression of portal hypertension. *Dig Liver Dis* 2008;40:62–67.

166. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, Escorsell A, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. *N Engl J Med* 2005;353:2254–2261.

167. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, Bortzio M, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. *Am J Gastroenterol* 2009;104:1147–1158.

168. Zuprich A, Garcia-Tsao G, Rogowski S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. *Liver Int* 2012;32:1407–1414.

169. Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, Blasco H, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. *Hepatology* 2017;66:1980–1988.

170. Stafylidou M, Paschos P, Katsoulia A, Malandris K, Ioakim K, Bekiari E, Haidich A-B, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2019;17(1744–1755):e1711.

171. Zheng KI, Liu C, Li J, Huang Y, Zhao L, Li S, Zhou L, et al. Validation of Baveno VI and Expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis. *J Hepatol* 2020.

172. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology* 2017;65:310–335.

173. Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. *J Hepatol* 2012;56:696–703.

174. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanchupatkul M, Richardson PA, Li L, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. *Gastroenterology* 2018;155(1828–1837):e1822.

175. Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. *Gastroenterology* 2020;158(1999–2014):e1991.

176. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What's in a name? Renaming 'NAFLD' to 'MAFLD'. *Liver Int* 2020. <https://doi.org/10.1111/liv.14478>.

177. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. *Hepatology* 2018;67:358–380.

178. Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology* 2020;158:1822–1830.

179. Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J Hepatol* 2020;72:250–261.

180. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017;11:317–370.

181. Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update. *Hepatol Res* 2019;49:1109–1113.

182. Korean Liver Cancer A, Center NC, GK. Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. *Korean J Radiol* 2018;20(20):1042–1113.

183. Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, Waljee AK, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. *Gastroenterology* 2018;154(1706–1718):e1701.

184. Mikami S, Tateishi R, Hagiwara S, Sato M, Minami T, Uchino K, Enooku K, et al. Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography. *Hepatol Res* 2015;45:415–422.

185. Kudo M, Ueshima K, Osaki Y, Hirooka M, Imai Y, Aso K, Numata K, et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. *Liver Cancer* 2019;8:271–280.

186. Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, Lee SS, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN). *Radiology* 2019;292:638–646.

187. Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, Choi SH, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. *J Hepatol* 2020;72:718–724.

188. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, Di Nolfo MA, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010;53:291–297.

189. Barbara L, Benzi G, Gaiani S, Fusconi F, Zironi G, Siringo S, Rigamonti A, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. *Hepatology* 1992;16:132–137.

190. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, Friedman SL, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology* 2015;149(367–378):e365.

191. Wong VW-S, Chan RS-M, Wong GL-H, Cheung BH-K, Chu WC-W, Yeung DK-W, Chim AM-L, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. *J Hepatol* 2013;59:536–542.

192. Jin YJ, Kim KM, Hwang S, Lee SG, Ha TY, Song GW, Jung DH, et al. Exercise and diet modification in non-obese non-alcoholic fatty liver disease: Analysis of biopsies of living liver donors. *J Gastroenterol Hepatol* 2012;27:1341–1347.

193. Hall KD, Guo J. Obesity energetics: body weight regulation and the effects of diet composition. *Gastroenterology* 2017;152(1718–1727):e1713.

194. Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. *J Clin Gastroenterol* 2012;46:457–467.

195. Estruch R, Ros E, Salas-Salvadó J, Covas M-I, Corella D, Arós F, Gómez-Gracia E, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013;368:1279–1290.

196. Gepner Y, Shelef I, Schwarzfuchs D, Zelicha H, Tene L, Yaskolka Meir A, Tsaban G, et al. Effect of distinct lifestyle interventions on mobilization of fat storage pools: CENTRAL magnetic resonance imaging randomized controlled trial. *Circulation* 2018;137:1143–1157.

197. Markova M, Pivovarova O, Hornemann S, Sucher S, Frahnow T, Wegner K, Machann J, et al. Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes. *Gastroenterology* 2017;152(571–585):e578.

198. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, McManus K, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. *N Engl J Med* 2009;360:859–873.

199. Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2017;29:e8–12.

200. Dudekula A, Rachakonda V, Shaik B, Behari J. Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. *PLoS One* 2014. <https://doi.org/10.1371/journal.pone.0111808>.

201. Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, Bugianesi E, et al. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. *J Hepatol* 2018;69:1155–1163.

202. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee I-M, Nieman DC, et al. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. *Med Sci Sports Exerc* 2011;43:1334–1359.

203. Orci LA, Gariani K, Oldani G, Delaune V, Morel P, Toso C. Exercise-based interventions for nonalcoholic fatty liver disease: a meta-analysis and meta-regression. *Clin Gastroenterol Hepatol* 2016;14:1398–1411.

204. Oh S, So R, Shida T, Matsuo T, Kim B, Akiyama K, Isobe T, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. *Sci Rep* 2017;7:43029.

205. Saran U, Humar B, Kolly P, Dufour J-F. Hepatocellular carcinoma and lifestyles. *J Hepatol* 2016;64:203–214.

206. Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, Calleja JL, et al. Effects of an intensive life-style intervention program on portal hypertension in patients with cirrhosis and obesity: the SportDiet study. *Hepatology* 2017;65:1293–1305.

207. Zhang H-J, He J, Pan L-L, Ma Z-M, Han C-K, Chen C-S, Chen Z, et al. Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial. *JAMA Internal Med* 2016;176:1074–1082.

208. Sung K-C, Ryu S, Lee J-Y, Kim J-Y, Wild SH, Byrne CD. Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. *J Hepatol* 2016;65:791–797.

209. Oh S, Shida T, Yamagishi K, Tanaka K, So R, Tsujimoto T, Shoda J. Moderate to vigorous physical activity volume is an important factor for managing nonalcoholic fatty liver disease: a retrospective study. *Hepatology* 2015;61:1205–1215.

210. Hashida R, Kawaguchi T, Bekki M, Omoto M, Matsuse H, Nago T, Takano Y, et al. Aerobic vs resistance exercise in non-alcoholic fatty liver disease: a systematic review. *J Hepatol* 2017;66:142–152.

211. Golabi P, Locklear CT, Austin P, Afdhal S, Byrns M, Gerber L, Younossi ZM. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. *World J Gastroenterol* 2016;22:6318.

212. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. *Hepatology* 2018;67:328–357.

213. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. *Cochrane Database Syst Rev* 2010. <https://doi.org/10.1002/14651858.CD007340.pub2>.

214. Seki Y, Kakizaki S, Horiguchi N, Hashizume H, Tojima H, Yamazaki Y, Sato K, et al. Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery. *J Gastroenterol* 2016;51:281–289.

215. Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery. *Surg Obes Relat Dis* 2015;11:137–141.

216. Aguilar-Olivos NE, Almeda-Valdes P, Aguilar-Salinas CA, Uribe M, Mendez-Sanchez N. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. *Metabolism* 2016;65:1196–1207.

217. Clanton J, Subichin M. The effects of metabolic surgery on fatty liver disease and nonalcoholic steatohepatitis. *Surg Clin North Am* 2016;96:703–715.

218. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? *J Obes* 2013. <https://doi.org/10.1155/2013/839275>.

219. Lassailly G, Caiazzo R, Ntandja-Wandji L-C, Gnemmi V, Baud G, Verkindt H, Ningarhari M, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. *Gastroenterology* 2020. <https://doi.org/10.1053/j.gastro.2020.06.006>.

220. Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. *Clin Gastroenterol Hepatol* 2011;9:897–901.

221. Lee Y, Doumouras AG, Yu J, Brar K, Banfield L, Gmora S, Anvari M, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2019;17(1040–1060):e1011.

222. Salomone F, Sharaiha RZ, Boškoski I. Endoscopic bariatric and metabolic therapies for non-alcoholic fatty liver disease: Evidence and perspectives. *Liver Int* 2020. <https://doi.org/10.1111/liv.14441>.

223. European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016;64:1388–1402.

224. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *N Engl J Med* 2006;355:2297–2307.

225. Cusi K, Orsak B, Bril F, Lomonaco R, Hecht J, Ortiz-Lopez C, Tio F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. *Ann Intern Med* 2016;165:305–315.

226. Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2012;35:66–75.

227. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. *Gastroenterology* 2008;135:1176–1184.

228. Tolman KG, Freston JW, Kupfer S, Perez A. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. *Drug Saf* 2009;32:787–800.

229. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *N Engl J Med* 2010;362:1675–1685.

230. Mehtala J, Khanfir H, Bennett D, Ye Y, Korhonen P, Hoti F. Pioglitazone use and risk of bladder cancer: a systematic literature review and meta-analysis of observational studies. *Diabetol Int* 2019;10:24–36.

231. Portillo-Sanchez P, Bril F, Lomonaco R, Barb D, Orsak B, Bruder JM, Cusi K. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial. *J Diabetes* 2019;11:223–231.

232. Armstrong MJ, Houlihan DD, Rowe IA, Clausen WH, Elbrond B, Gough SC, Tomlinson JW, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. *Aliment Pharmacol Ther* 2013;37:234–242.

233. Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, Hazlehurst JM, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. *Lancet* 2016;387:679–690.

234. Tang W, Xu Q, Hong T, Tong G, Feng W, Shen S, Bi Y, et al. Comparative efficacy of anti-diabetic agents on nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized and non-randomized studies. *Diabetes Metab Res Rev* 2016;32:200–216.

235. Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol* 2017;41:284–295.

236. Shah M, Vella A. Effects of GLP-1 on appetite and weight. *Rev Endocr Metab Disord* 2014;15:181–187.

237. Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, et al. Luseogliflozin improves liver fat deposition

compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study. *Diabetes Obes Metab* 2018;20:438–442.

238. Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). *Diabetes Care* 2018;41:1801–1808.

239. Cusi K, Bril F, Barb D, Polidori D, Sha S, Ghosh A, Farrell K, et al. Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. *Diabetes Obes Metab* 2019;21:812–821.

240. Lai L-L, Vethakkan SR, Mustapha NRN, Mahadeva S, Chan W-K. Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus. *Dig Dis Sci* 2020;65:623–631.

241. Haukeland JW, Konopski Z, Eggesbo HB, von Volkmann HL, Raschpichler G, Bjoro K, Haaland T, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. *Scand J Gastroenterol* 2009;44:853–860.

242. Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. *Hepatology* 2010;52:79–104.

243. Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. *JAMA* 2011;305:1659–1668.

244. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Biomed Rep* 2013;1:57–64.

245. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Eslam M, Lai-Hung GW, et al. Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related, child-pugh a cirrhosis. *Clin Gastroenterol Hepatol* 2020. <https://doi.org/10.1016/j.cgh.2020.04.083>.

246. Zhou J, Ke Y, Lei X, Wu T, Li Y, Bao T, Tang H, et al. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes. *Ann Hepatol* 2020;19:320–328.

247. Harrison SA, Torgerson S, Hayashi P, Ward J, Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. *Am J Gastroenterol* 2003;98:2485–2490.

248. Hoofnagle JH, Van Natta ML, Kleiner DE, Clark JM, Kowdley KV, Loomba R, Neuschwander-Tetri BA, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis. *Aliment Pharmacol Ther* 2013;38:134–143.

249. Sato K, Gosho M, Yamamoto T, Kobayashi Y, Ishii N, Ohashi T, Nakade Y, et al. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. *Nutrition* 2015;31:923–930.

250. Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. *Saudi J Gastroenterol* 2014;20:143–153.

251. Amanullah I, Khan YH, Anwar I, Gulzar A, Mallhi TH, Raja AA. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials. *Postgrad Med J* 2019;95:601–611.

252. Bril F, Biernacki DM, Kalavalapalli S, Lomonaco R, Subbarayan SK, Lai J, Tio F, et al. Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial. *Diabetes Care* 2019;42:1481–1488.

253. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. *Hepatology* 2020;71:495–509.

254. Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2011;306:1549–1556.

255. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramini H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Cochrane Database Syst Rev* 2013. <https://doi.org/10.1002/14651858.CD008623.pub2>.

256. Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, Pagourelas ED, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. *Lancet* 2010;376:1916–1922.

257. Khoo S, Wong VWS, Goh GBB, Fan J, Chan WK, Seto WK, Chow WC. Suboptimal treatment of dyslipidemia in patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol* 2020;35:320–325.

258. Du J, Ma Y-Y, Yu C-H, Li Y-M. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. *World J Gastroenterol* 2014;20:569.

259. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. *World J Gastroenterol* 2018;24:3361.

260. Liver EAfTSoT, Diabetes EAfTSo. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *Obes Facts* 2016;9:65–90.

261. Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, et al. Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. *Gastroenterology* 2020. <https://doi.org/10.1053/j.gastro.2020.01.043>.

262. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. *Clin Gastroenterol Hepatol* 2015;13(643–654):e649.

263. Kaya E, Bakir A, Kani HT, Demirtas CO, Keklikiran C, Yilmaz Y. Simple noninvasive scores are clinically useful to exclude, not predict, advanced fibrosis: a study in Turkish patients with biopsy-proven nonalcoholic fatty liver disease. *Gut Liver* 2019. <https://doi.org/10.5009/gnl19173>.

264. Jafarov F, Kaya E, Bakir A, Eren F, Yilmaz Y. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven non-alcoholic fatty liver disease study. *Eur J Gastroenterol Hepatol* 2020;32:642–649.

265. Dulai PS, Sirlin CB, Loomba R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. *J Hepatol* 2016;65:1006–1016.

266. Younossi ZM. Patient-reported outcomes and the economic effects of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: the value proposition. *Hepatology* 2018;68:2405–2412.

267. Doward L, Balp MM, Twiss J, Slota C, Cryer D, Langford A, Collen R, et al. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis. *J Hepatol* 2018;68:S570.

268. Younossi ZM, Stepanova M, Henry L, Racila A, Lam B, Pham HT, Hunt S. A disease-specific quality of life instrument for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: CLDQ-NAFLD. *Liver Int* 2017;37:1209–1218.

269. Dan AA, Kallman JB, Wheeler A, Younossi Z, Collantes R, Bondini S, Gerber L, et al. Health-related quality of life in patients with non-alcoholic fatty liver disease. *Aliment Pharmacol Ther* 2007;26:815–820.

270. David K, Kowdley KV, Unalp A, Kanwal F, Brunt EM, Schwimmer JB, Group NCR. Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network. *Hepatology* 2009;49:1904–1912.

271. Golabi P, Otgonsuren M, Cable R, Felix S, Koenig A, Sayiner M, Younossi ZM. Non-alcoholic fatty liver disease (NAFLD) is associated with impairment of Health Related Quality of Life (HRQOL). *Health Qual Life Outcomes* 2016;14:18.

272. Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, et al. Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2019;17(2552–2560):e2510.

273. Huber Y, Boyle M, Hallsworth K, Tiniakos D, Straub BK, Labenz C, Ruckes C, et al. Health-related quality of life in non-alcoholic fatty liver disease associates with hepatic inflammation. *Clin Gastroenterol Hepatol* 2019;17(2085–2092):e2081.

274. Sumida Y, Okanoue T, Nakajima A, NAFLD JSGo. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. *Hepatol Res* 2019;49:1256–1262.

275. Eslam M, Alvani R, Shiha G. Obeticholic acid: towards first approval for NASH. *Lancet* 2019. [https://doi.org/10.1016/S0140-6736\(19\)32963-0](https://doi.org/10.1016/S0140-6736(19)32963-0).

276. Shah RA, Kowdley KV. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. *Expert Rev Gastroenterol Hepatol* 2020. <https://doi.org/10.1080/17474124.2020.1748498>.

277. Younossi ZM, Ratiu V, Loomba R, Rinella M, Anstee QM, Goodman Z, Bedossa P, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. *Lancet* 2019;394:2184–2196.

278. Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, et al. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. *Liver Int* 2019;39:2082–2093.

279. Ratiu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, et al. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. *Contemp Clin Trials* 2019;84:105803.

280. Ratiu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor- α and- δ , induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. *Gastroenterology* 2016;150(1147–1159):e1145.

281. Harrison SA, Wong VW-S, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized Ph III STELLAR trials. *J Hepatol*. 2020;73(1):26–39.

282. Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. *Expert Opin Investig Drugs* 2018;27:301–311.

283. Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet* 2019;394:2012–2024.

284. Safadi R, Konikoff FM, Mahamid M, Zelber-Sagi S, Halpern M, Gilat T, Oren R, et al. The fatty acid–bile acid conjugate aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol* 2014;12(2085–2091):e2081.

285. Chen F, Esmaili S, Rogers G, Bugianesi E, Petta S, Marchesini G, Bayoumi A, et al. Lean NAFLD: a distinct entity shaped by differential metabolic adaptation. *Hepatology* 2019. <https://doi.org/10.1002/hep.30908>.

286. Rastogi A, Shastry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease-histological scoring systems: a large cohort single-center, evaluation study. *APMIS* 2017;125:962–973.

287. Wong VW-S, Wong GL-H, Chan RS-M, Shu SS-T, Cheung BH-K, Li LS, Chim AM-L, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. *J Hepatol* 2018;69:1349–1356.

288. Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. *Eur J Gastroenterol Hepatol* 2020;32(10):1352–1357.

289. Alam S, Hasan MJ, Khan MAS, Alam M, Hasan N. Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient. *J Transl Internal Med* 2019;7:106–114.

290. Utz-Melere M, Targa-Ferreira C, Lessa-Horta B, Epifanio M, Mouzaki M, Mattos AA. Non-alcoholic fatty liver disease in children and adolescents: lifestyle change. A systematic review and meta-analysis. *Ann Hepatol* 2018;17:345–354.

291. Tokushige K, Hyogo H, Nakajima T, Ono M, Kawaguchi T, Honda K, Eguchi Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey. *J Gastroenterol* 2016;51:586–596.

292. Pais R, Fartoux L, Goumar C, Scatton O, Wendum D, Rosmorduc O, Ratiu V. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. *Aliment Pharmacol Ther* 2017;46:856–863.

293. Bengtsson B, Stal P, Wahlin S, Bjorkstrom NK, Hagstrom H. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis. *Liver Int* 2019;39:1098–1108.

294. Billeter AT, Muller PC, Albrecht T, Roessler S, Loffler M, Lemekhova A, Mehrabi A, et al. Impact of type 2 diabetes on oncologic outcomes of hepatocellular carcinomas in non-cirrhotic, non-alcoholic steatohepatitis: a matched-pair analysis. *J Gastrointest Surg* 2020. <https://doi.org/10.1007/s11605-020-04628-0>.

295. Mohamad B, Shah V, Onyshchenko M, Elshamy M, Aucejo F, Lopez R, Hanouneh IA, et al. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. *Hepatol Int* 2016;10:632–639.

296. Fahira A, Hanifah RS, Wardoyo MP, Diba AD, Ramadhan R, Barliana JD, Jasirwan CO. Is higher BMI associated with worse overall mortality in hepatocellular carcinoma patients? An evidence based case report. *Acta Med Indones* 2019;51:356–363.

297. Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watanuki T, Nakagomi R, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. *J Hepatol* 2015;63:131–140.

298. Li Q, Xing H, Liu D, Li H. Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma. *World J Surg Oncol* 2015;13:294.

299. Harimoto N, Shirabe K, Yamashita YI, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, et al. Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma. *Br J Surg* 2013;100:1523–1530.

300. Harimoto N, Yoshizumi T, Shimokawa M, Sakata K, Kimura K, Itoh S, Ikegami T, et al. Sarcopenia is a poor prognostic factor following hepatic resection in patients aged 70 years and older with hepatocellular carcinoma. *Hepatol Res* 2016;46:1247–1255.

301. Nishikawa H, Nishijima N, Enomoto H, Sakamoto A, Nasu A, Komekado H, Nishimura T, et al. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma undergoing sorafenib therapy. *Oncol Lett* 2017;14:1637–1647.

302. Ha Y, Kim D, Han S, Chon YE, Lee YB, Kim MN, Lee JH, et al. Sarcopenia predicts prognosis in patients with newly diagnosed hepatocellular carcinoma, independent of tumor stage and liver function. *Cancer Res Treat* 2018;50:843–851.

303. Imai K, Takai K, Watanabe S, Hanai T, Suetsugu A, Shiraki M, Shimizu M. Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: the role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume. *Nutrients* 2017. <https://doi.org/10.3390/nu9101054>.

304. Takada H, Kuroasaki M, Nakanishi H, Takahashi Y, Itakura J, Tsuchiya K, Yasui Y, et al. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. *PLoS One* 2018;13:e0198812.

305. Mardian Y, Yano Y, Ratnasari N, Choridah L, Wasityastuti W, Setyawan NH, Hayashi Y. Sarcopenia and intramuscular fat deposition are associated with poor survival in Indonesian patients with hepatocellular carcinoma: a retrospective study. *BMC Gastroenterol* 2019;19:229.

306. Hashida R, Kawaguchi T, Koya S, Hirota K, Goshima N, Yoshiyama T, Otsuka T, et al. Impact of cancer rehabilitation on the prognosis of patients with hepatocellular carcinoma. *Oncol Lett* 2020;19:2355–2367.

307. Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, et al. A Data Mining-based prognostic algorithm for NAFLD-related hepatoma patients: a nationwide study by the Japan Study Group of NAFLD. *Sci Rep* 2018;8:10434.

308. Calzadilla-Bertot L, Jeffrey GP, Jacques B, McCaughey G, Crawford M, Angus P, Jones R, et al. Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand. *Liver Transpl* 2019;25:25–34.

309. Narasimhan G, Kota V, Rela M. Liver transplantation in India. *Liver Transpl* 2016;22:1019–1024.

310. Serin A, Sahin T, Arikan BT, Emek E, Bozkurt B, Tokat Y. A changing etiologic scenario in liver transplantation: a single-center cohort study from Turkey. *Transpl Proc* 2019;51:2416–2419.

311. Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J, et al. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a European Liver Transplant Registry study. *J Hepatol* 2019;71:313–322.

312. O’Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. *Clin Gastroenterol Hepatol* 2011;9(700–704):e701.

313. Patel SS, Nabi E, Guzman L, Abbate A, Bhati C, Stravitz RT, Reichman T, et al. Coronary artery disease in decompensated patients undergoing liver transplantation evaluation. *Liver Transpl* 2018;24:333–342.

314. Konerman MA, Fritze D, Weinberg RL, Sonnenday CJ, Sharma P. Incidence of and risk assessment for adverse cardiovascular outcomes after liver transplantation: a systematic review. *Transplantation* 2017;101:1645–1657.

315. VanWagner LB, Serper M, Kang R, Levitsky J, Hohmann S, Abecassis M, Skaro A, et al. Factors associated with major adverse cardiovascular events after liver transplantation among a national sample. *Am J Transpl* 2016;16:2684–2694.

316. VanWagner LB, Lapin B, Skaro AI, Lloyd-Jones DM, Rinella ME. Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. *Liver Int* 2015;35:2575–2583.

317. Stine JG, Shah NL, Argo CK, Pelletier SJ, Caldwell SH, Northup PG. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. *Liver Transpl* 2015;21:1016–1021.

318. Gaballa D, Bezinover D, Kadry Z, Eyster E, Wang M, Northup PG, Stine JG. Development of a model to predict portal vein thrombosis in liver transplant candidates: the portal vein thrombosis risk index. *Liver Transpl* 2019;25:1747–1755.

319. Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. *Dig Dis Sci* 2017;62:2915–2922.

320. Bhati C, Idowu MO, Sanyal AJ, Rivera M, Driscoll C, Stravitz RT, Kohli DR, et al. Long-term outcomes in patients undergoing liver transplantation for nonalcoholic steatohepatitis-related cirrhosis. *Transplantation* 2017;101:1867–1874.

321. Taneja S, Roy A. Nonalcoholic steatohepatitis recurrence after liver transplant. *Transl Gastroenterol Hepatol* 2020;5:24.

322. Patel SS, Rodriguez VA, Siddiqui MB, Faridnia M, Lin FP, Chandrakumaran A, Laurenzano J, et al. The impact of coronary artery disease and statins on survival after liver transplantation. *Liver Transpl* 2019;25:1514–1523.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.